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Abstract 
The widespread use of antibiotics has led to dramatic increases in the incidence and severity of 
Clostridium difficile infection (CDI). No group of patients suffers more from CDI than the 
elderly. Nursing homes (NH) represent the perfect storm of a vulnerable group of frail elders 
living in confined communities. Nursing home residents suffer from increased morbidity and 
mortality from CDI and corresponding high rates of C. difficile colonization. Upwards of 40 to 
50% of CDI current cases originate from NHs and the prevalence of colonization rates remain 
high within these facilities, with as many as half of the residents being colonized with C. difficile 
at any given time. One factor that has become of increasing interest and a target of preventive 
strategies is the human intestinal microbiome. A healthy, diverse microbiome interacts with the 
host immune system and contributes to pathogen resistance. In this investigation, we first 
examine elder specific variables to determine if the associated risks of CDI differ by home living 
environment (nursing home versus community-dwelling). We then go on explore the 
relationships of NH environment, frailty, nutritional status, and residents’ age with microbiome 
composition and potential metabolic function. Finally, we describe the C. difficile colonization 
patterns among elderly NH residents and the associated risk of colonization based on clinical 
variables and microbiome determinants. A better understanding of the microbiome’s contribution 
to C. difficile colonization will provide the basis for informing rational interventions and public 
health policies to better combat CDI in the nursing home. 
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INTRODUCTION 
1. Overview 
Clostridium difficile is an anaerobic, motile bacteria that is a member of the genus 
Clostridium and the Clostridiaceae family. This bacterium is ubiquitous in nature with a strong 
prevalence in soil. However C. difficile shows optimum growth on blood agar plates at human 
body temperatures. It is a Gram-positive organism that is rod shaped, pleomorphic, and occurs in 
pairs or short chains. [1] In 1935, C. difficile was first identified in the stool of healthy newborns. 
However it was not until four decades later, in 1978 when it was first identified as a causative 
agent in human cases of antibiotic-associated diarrhea. [2] It was not until March of 2003 when 
several hospitals in Quebec, Canada first noted a marked increase in the incidence of Clostridium 
difficile-associated diarrhea. [3] Since that time the prevalence and virulence of Clostridium 
difficile infections (CDI) in Western countries have been increasing [4, 5] and CDI is now the 
leading cause of gastroenterologic hospitalizations and associated deaths.[6] 
 
C. difficile produces two major types of toxins, enterotoxin A and cytotoxin B. [7] These 
toxins can disrupt the cytoskeleton and signal transduction in the human intestine. When humans 
are exposed to these toxins they generally develop colonic inflammation leading to the major 
disease manifestation of diarrhea. Diarrheal symptoms range from a few days of watery stools to 
potential life-threatening pseudomembranous colitis. The toxins expressed by C. difficile are this 
organism's main virulence factor and it is believed that the presence of toxin in stool is a positive 
correlate of disease. [20] 
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C. difficile is only one causative mechanism of diarrhea after antibiotic exposure.  
Antibiotic-associated diarrhea (AAD), a common side effect of antibiotic administration, 
complicates between 5% to 39% of treatment regimens. [8] The frequency of AAD is influenced 
by antibiotic selection and by patient characteristics, including comorbidities and age. [9] C. 
difficile infection is responsible for 10-20% of all AAD cases and is thus an important part of 
AAD given it carries most of the morbidity and mortality associated with this disease. [8] It also 
makes diagnosing CDI in a patient with AAD critical to targeted therapy. Although virtually all 
antibiotics have been implicated in CDI, the cephalosporins, clindamycin, and broad-spectrum 
penicillins have higher associated risks of disease. [10]  Prolonged courses of antibiotic 
treatment, administration of multiple antibiotics, patient age >65 years, or history of diarrhea 
following antibiotic use impart additional risk. [8, 11, 12] The great majority of patients who 
develop CDI do so within the first two weeks of antibiotic exposure, [13] but AAD can occur at 
any time, including up to 2−3 weeks following cessation of antibiotic therapy. [11]  
 
What makes C. difficile particularly difficult to deal with is the fact that it is a spore 
forming bacterium.  When under stress C. difficile produces spores which are able tolerate 
extreme conditions. [2] The major route of transmission, which is from person to person via the 
fecal-oral route, is attributed to the presence of these spores in the feces. These spores can 
contaminate any surface including toilets, bathing tubs, and medical equipment. These surfaces 
can then serve as a reservoir for transmission. In the hospital environment transmission mainly 
occurs via the hands of healthcare workers who come in contact with those surfaces harboring C. 
difficile spores. These spores are hardy and can live for long periods of time on surfaces, which 
is upwards of 5 months on solid surfaces. [14, 15] Accordingly, hospital policies presently focus 
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on environmental measures to control CDI by enforcing hand hygiene, contact precautions, and 
decontamination procedures after CDI is identified. [16] These interventions aimed at reducing 
C. difficile transmission have had only a minimal impact on stemming the alarming increase in 
C. difficile cases. Unfortunately, these heat-resistant spores survive in clinical environments even 
after routine cleaning procedures are performed. Once C. difficile spores are ingested they easily 
transit through the stomach unscathed, due to their acid-resistance properties. Once the spores 
become exposed to bile acids within the colon they then germinate and multiply into vegetative 
cells. 
In summary, C. difficile is a very important nosocomial infection that is difficult to 
contain. with..  Clearly an important element in dealing with it is accurately diagnosing it. 
 
Diagnosis of Clostridium difficile Infection 
In order to diagnose a patient with CDI two conditions need to be met. [17] First, the 
patient must have diarrheal symptoms defined as three or more loose stools per day for two or 
more consecutive days. [11, 18] Second, there must be a stool test result positive for the presence 
of C. difficile toxins or colonoscopic findings demonstrating pseudomembranous colitis. Most 
patients are diagnosed by toxin assays rather than colonoscopy. The gold standard for the 
diagnosis of CDI is the cytotoxin assay test in tissue culture. [8] It is the most sensitive test, 
being able to detect as little as 10 pg of toxin. [19] However, due to its expensive nature, this 
diagnostic test has been abandoned by most clinical laboratories. Instead laboratories rely on 
either immunoassays or nucleic acid amplification test (NAAT) assays to detect C. difficile 
toxins presence. The enzyme immunoassay (EIA) has the advantage of detecting toxin antigen 
when performed on stool samples thus directly assessing toxin production. Toxin EIA is 
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unfortunately associated with widely varying sensitivities (50 to 99%) and specificities (70 to 
100%) making its reliability questionable for an accurate diagnostic of CDI. [17] In 2010, the 
Society for Healthcare Epidemiology (SHEA) and the Infectious Diseases Society of American 
(IDSA) indicated that toxin EIAs were no longer sufficient as standalone diagnostic tests for 
CDI. [17]  
 
The alternative, the EIA test, functions by detection of toxin genes by NAATs via 
polymerase chain reaction (PCR). The disadvantage of NAATs is that gene presence does not 
mean active toxin production. These assays have greater than 90% sensitivities and specificities, 
thus making them the current standard detection test of C. difficile presence for clinical 
laboratory use. [21] The significance of a positive NAAT test and EIA test is unclear. Since 
NAATs will detect colonization of C. difficile as well as infective states, there is a concern that 
NAATs testing is leading to over diagnosis and over treatment of CDI. [22] Very few well-
controlled studies have established the clinical efficacy of using EIA and NAATs in parallel for 
the diagnosis of CDI. Nonetheless, several test algorithms have been developed to improve the 
rapid and accurate diagnosis of CDI (Figure 1). The European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) recommends the use of a two-step algorithm which starts 
with NAATs. When the NAAT is positive then continuation on to a secondary confirmatory step 
with toxin-EIA is necessary before a sample can be reported as positive for CDI. [23] 
Performance of this diagnostic approach still needs further evaluation and validation.  
 
Recurrent Clostridium difficile Infection 
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One of the troubling complications that arises from C. difficile treatment is the high rate 
of recurrent infections. The increasing incidence of recurrent Clostridium difficile infection 
(rCDI) has been alarming with an almost 200% increase from 2001 to 2012. [24] Patients remain 
vulnerable to rCDI for months or even years after initial CDI treatment. [25] Recurrent infection 
is common, occurring in up to 22% of initial cases.[26] Recurrent CDI includes both relapse and 
reinfection with a new strain. [27] The relative frequency of relapse versus reinfection has not 
been well described. From limited published data, it is believed that anywhere from 33% to 75% 
of cases of rCDI can be attributed to infection by a new strain. [25] The Centers for Disease 
Control and Prevention (CDC) defines the window for rCDI to occur between 2 to 8 weeks after 
the last positive specimen was tested, however many believe this risk extends out to 1 year. [28] 
Since most patients do not undergo routine stool sample testing, other investigators have adopted 
a definition of recurrence that extends up to 90 days after completion of treatment. [29] It has 
however been shown that the risk may extend out to one year, especially when considering a 
patients risk of reinfection. [30] In fact it may take as long as 1-2 years for certain normal 
intestinal microbial species to recover after antimicrobial therapy. [31] 
 
The exact mechanism for recurrence is unknown. The most common risk factors for 
recurrence are advanced age, comorbidities, use of antibiotics after CDI diagnosis, and gastric 
acid-suppressive therapy. [26, 32] Both of the acid reducing medications, histamine-2 receptor 
antagonists and proton pump inhibitors, have been linked to CDI. [33, 34] The judicious use of 
antibiotics and proton pump inhibitors may play an important role in the prevention of rCDI. [35] 
The roles of other medications such as corticosteroids are less clear as they have been shown to 
both increase and decrease the risk of incidence of and mortality from CDI and rCDI. [36-39] 
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Clostridium difficile and the Elderly 
Extensive use of antibiotics has resulted in a dramatic increase in the magnitude of CDI 
especially among older adults. [4, 5] Clostridium difficile infection disproportionally affects the 
elderly population. [40, 41] The increased risk burden begins at age 65[42] and increases by 2% 
for each additional year of aging. [43] Not only are elders at increased risk of acquiring CDI but 
they also have higher rates of complications, recurrence, and death. [26] Recently, the burden of 
CDI has shifted with a predominance of elderly patients affected being from a nursing homes 
(NHs) and not the hospital setting. [40, 44] Upwards of 40 to 50% of CDI cases are now from 
NHs. [45, 46] Residing in an NH is also a significant predictor of increased CDI disease severity. 
[47, 48] The presence of frailer elders in the NH with multiple comorbidities, are associated with 
an increased risk of CDI; these risk factors alone, however, do not adequately or completely 
explain the increased risk.  
 
Nursing homes provide two types of care to elders. The first is custodial care or care that 
is primarily non-medical in nature. This care is supportive of activities of daily living. The 
second type of care is skilled nursing care where elders require more intensive medical, nursing, 
and rehabilitative services typically after discharge from the hospital setting for an acute illness. 
Nursing homes typically provide both custodial care and skilled nursing care.  Thus nursing 
homes can be referred to as both long-term care facilities (LTCFs) or skilled nursing facilities 
(SNFs). The short-stay and long-stay resident populations in facilities differ in burden of 
illness,[49] functional status,[49] and risk for bacterial colonization and infection. [50] However, 
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these groups of residents are sometimes mixed when reporting disease outcomes. Both groups 
share in an increased risk of both CDI and C. difficile colonization.   
 
It remains a challenge to conduct research in the nursing home environment. Issues 
surrounding informed consent and the protection of human rights make it a challenge to conduct 
research among nursing homes elders. [51] Characteristics of the nursing homes, the staff, and 
the residents living there also present difficult hurdles in conducting elder research in this 
settings. Much time and effort are required for the investigator to get all three NH tiers 
(administrators, nursing, and residents) to buy in to participation in human subjects research to 
make any investigation successful. This does not even take into account the family and ancillary 
staff that can be essential to NH research success. Because of these hurdles, research focused on 
NH elders has been lacking, especially with studies involving primary data and specimen 
collection. These hurdles need to be cleared to drive investigations among NH elders. This is of 
critical importance given that NH elders now are at the center of the C. difficile epidemic.  
 
The intestinal microbiome and Clostridium difficile colonization 
One factor that has become of increasing contemporary interest and a target of preventive 
strategies is the human microbiome. The microbiome is a vast array of microbes that influence 
human health and disease. [52] The intestinal flora changes with age, especially as the presence 
of anaerobes decreases. [53, 54] Elders from NHs differ from community-dwelling counterparts 
in their microbiome composition with higher proportions of the phylum Bacteroidetes and lower 
proportions of other bacteria at the family and genus levels. [55] 
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C. difficile can be considered a member of the normal gut bacterial flora. It is not a 
dominant member and its growth is suppressed by the more dominant anaerobes present. In fact, 
the healthy microbiota of the large intestine is thought to act as a barrier effect in resisting 
colonization to C. difficile.[56] The intestinal microbiota is known to be intrinsically stable with 
a sub-network of bacterial groups implicated in protection against CDI. [57] The rates of C. 
difficile present in the microbiome are the highest in NHs, with 20% to 50% of residents affected 
compared with 1.6% in the general community and 9.5% in the outpatient settings. [53, 58] 
Colonization with C. difficile is a well-documented source of new CDI cases, however 
approaches to managing carriage as a means to prevent CDI are lacking. [59-61]  
 
By altering the structure of the gut microbiome, antibiotics alter its function leading to a 
loss in resistance to growth of C. difficile and an increased risk of CDI and diarrhea. [62] CDI 
requires the right combination of favorable growth conditions resulting from microbiome 
community alterations (i.e. after antibiotic administration) and the presence of the bacterium C. 
difficile to lead to CDI. Certain disruptions in the microbiota allow C. difficile to proliferate and 
cause CDI while other microbiome states allow for colonization but resist CDI (disease). 
Understanding this “at-risk for developing CDI” microbiome in relationship to a microbiome that 
permits colonization without disease development and/or one that resists both colonization and 
infection could provide a novel target for preventative strategies.  
 One term used when describing dysfunction within the microbiome is dysbiosis. 
Dysbiosis is a microbial imbalance or maladaption inside or on the human body. This occurs if 
the normal microbiome becomes deranged when bacterial species known to associate with or 
cause disease are present or are more in abundance than what is typical of that environment. 
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These “bad bacteria” are typically dominated by "healthy bacteria” that carry out benign or 
beneficial functions for the human host. Dysbiosis can refer to this bacterial presence or can refer 
to a balance of bacteria that then associate with human disease. Dysbiosis can also refer to 
derangements in the normal metabolism of a healthy microbiome.  
 
 
Microbiome Sciences 
 The intestinal microbiome plays a critical role in maintaining human health throughout 
life. The microbiome’s presence was not generally recognized until the late 1990s, but has an 
enormous impact on human health. Historically members of the microbiome were identified 
broadly by culture and in situ staining techniques. Thus, it was necessary to grow an organism in 
the lab to then identify and study it. These limited techniques led to an understanding of bacteria 
that were easily grown, but as a whole, represented a minority of the microbiome taxonomy 
composition. The development of culture-independent techniques, where DNA is directly 
extracted from a sample, made it possible to investigate the entirety of the microbiome.  
 
 DNA-based methods can generally be broken down into taxonomic and functional 
metagenomic diversity. [52] Taxonomic diversity refers to how many different organism types 
are present in the microbe community while functional metagenomics refers to describing the 
assigned biological tasks that members of this community have the potential to carry out. 
Currently microbiome-based investigations have analyzed community composition and 
metabolic profiles independently or focused on identifying statistical associations between these 
two data types. [63] Methods for integrating taxonomic and metabolic data are lagging but seem 
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to be at the forefront of the more recent novel analytical techniques developed and reported on in 
the literature.  
 
Technological advances in high-throughput sequencing have facilitated culture-
independent analysis of the microbiome that rely on either sequencing of the 16S ribosomal 
RNA or of the entire genome present. 16S ribosomal RNA (16S rRNA) is a critical component 
of cell function, is universal in bacteria, and is highly conserved between different species of 
bacteria. 16S rRNA has proven useful for bacterial identification due to its gene sequences 
containing hypervariable regions that can provide a species-specific signature sequence. [64] 
Comparisons of the bacterial 16S rRNA gene sequences has emerged as one preferred genetic 
technique for taxonomy comparisons. [64] In fact, the 16S rRNA technique is the most common 
sequencing approach used to analyze genomic data collected from the Human Microbiome 
Project. [65] 16S rRNA gene sequence analysis is superior to culture based techniques because it 
can better identify poorly described, rarely isolated strains, can lead to the recognition of novel 
pathogens, and can identify nonculturable bacteria.  
 
There are several limitations to the 16S rRNA methodology of microbiome 
investigations. First, the annotation is based on putative association of the 16S rRNA gene with 
taxa defined as an operational taxonomic unit (OTU). An OTU is an operational definition used 
to classify groups of closely related sequences used for analysis at the phyla or genera level. It is 
unfortunately less precise at the species level. [66] So, specific genes are not directly sequenced, 
but rather predicted based on the OTUs, and this lack of direct gene identification is a potential 
limitation in exploring and understanding the microbiome.  
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 An alternative to the16S rRNA technique is whole genome sequencing. Whole genome 
sequencing is a sequencing method that uses random primers to sequence overlapping regions of 
an entire genome. This technique will determine the complete DNA sequence of an entire 
microbiome, including bacterial, viral and archaea, at a single time. Whole genome sequencing 
has led to the term metagenomics. The metagenome refers to the collection of genes sequenced 
from one environmental sample that is analyzed in an analogous way to the study of single 
genomes. [67] One specific type of whole genome sequencing is referred to as shotgun 
metagenomics or whole metagenomic genome shotgun sequencing. Whole genome sequencing 
differs from 16S rRNA techniques in several key ways (Table 1). This approach randomly 
shears all the DNA from an environmental sample, sequences many short sequences, and 
reconstructs them into a consensus sequence (Figure 2). Shotgun metagenomics provides both 
information on the taxonomy of organisms present and the metabolic processes that are possible 
from the microbiota community. [68] Shotgun whole genome sequencing has multiple 
advantages when compared to the 16S method that include enhanced and improved detection 
accuracy of bacterial species, increased detection of diversity, and increased prediction of genes. 
[66] In addition, whole genome sequencing gives metabolic pathway information that is not 
attainable from the 16S rRNA approach. A major drawback to whole genome sequencing is the 
cost difference between the two techniques with 16S rRNA sequencing costing roughly 10 times 
less than whole genome sequencing. Whole genome sequencing also requires much more 
computer space to store the sequenced data. Nonetheless, we chose to use the shotgun 
metagenomic approach in this project due to the listed advantages above. 
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Metagenomic Analysis 
 The data obtained from metagenomic sequencing of a sample is enormous with 
fragmented data of upwards of 3 million genes from as many as 10,000 species that requires 
hundreds of gigabases of sequence data. [69] There are multiple steps that need to be taken to go 
from sample to data. The first steps after obtaining the data involve filtering the data for 
redundant, low-quality sequences. There are also programs available to remove eukaryotic 
genomic DNA sequences such as Eu-Detect. [70] The next step involves matching the sequences 
obtained from the sample to a reference library. Metagenomic Phylogenetic Analysis 
(MetaPhlAn) is a method based on unique clade-specific markers for estimating organismal 
relative abundances. [71] Alternatively, the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database is a collection of databases dealing with genomes, biological pathways, 
diseases, drugs, and chemical substances. [72] Thus, using MetaPhlAn will give taxonomy from 
whole genome sequencing and KEGG can be used to get functional metabolic diversity.  
 
 Once the genomic data is matched to a reference library, one of the first methods to 
explore the resultant data is to look at species diversity. The most common types of diversities 
are α and β-diversity. α-diversity is the biodiversity in a defined habitat or in the case of 
microbiome analysis the diversity within the sample. This asks the fundamental question of how 
many different species are detected in one sample. The Shannon index is a popular α-diversity 
index which quantifies the entropy or information content. [73] The Shannon index will perform 
well when approximating the microbial diversity of common taxa, however it may not be 
accurate when examining the numerous low abundant organisms present. [74]  
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β-diversity compares the diversity between habitats or samples. The question asked by β-
diversity is how different is the microbiome composition from one sample to the other. 
Commonly, two- or three-dimensional plots are used to visually represent the observed β-
diversity. Beta-diversity is a ‘distance’ measure of community similarity/dissimilarity. If two 
samples have very similar species composition, they will map close together (low dissimilarity) 
while samples with non-overlapping composition will map far apart (high dissimilarity). There 
forth, similar microbiomes from different samples will cluster together. Dissimilarity can be 
assessed on presence/absence of taxa (binary) or relative abundances (weighted). Distances can 
be measured with many different metrics. Two commonly used measures of β-diversity distances 
are Bray-Curtis or Jaccard. [75] The Jaccard similarity index is a way to compare populations by 
determining what percent of organisms identified were present in both samples. The Jaccard 
coefficient measures similarity between samples and is defined as the size of the intersection 
divided by the size of the union. The Jaccard distance is a metric distance, and measures the 
dissimilarity between samples. It is complementary to the Jaccard coefficient and is obtained by 
subtracting the Jaccard coefficient from 1. [76] Bray–Curtis dissimilarity is used to quantify the 
compositional dissimilarity between two samples. Bray–Curtis dissimilarity is often erroneously 
called a distance as it does not satisfy triangle inequality. [77] The choice between the binary and 
weighted methods can be made depending on what relevant information you are exploring. For 
example, if you want to think about bacterial species that may be protective against a disease 
process than binary methods may be more relevant. However, if you want to consider the impact 
of an intervention on the microbiome, then abundance methods may be preferred. 
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The distance measures from a large set of samples can be plotted in multi-dimensional 
space visualized in two- or three-dimensional scatterplots. Principal Component Analysis (PCA) 
is applied to the distance matrix to find the 2 or 3 dimensions (or principal coordinates) in which 
we can visualize the largest amount of distance variation (i.e. maximally spreads of the samples 
in space). The percentage of total variation explained by each axis is indicated on the axis. [78] 
When visualizing PCA using Jaccard one can start to explore if different subject specific 
variables associate with microbiome samples that cluster together. The non-parametric 
multivariate statistical test that is used to compare groups of objects is the permutational 
multivariate analysis of variance (PERMANOVA) test. The PERMANOVA tests the hypothesis 
that the centroids and dispersion of the groupings made by one covariate, as defined by measured 
space, are equivalent for all groups (Figure 3). A rejected null hypothesis means that either the 
centroid and/or the dispersion of the points is different between the groups. [79] The 
PERMANOVA tests is quite often the first step in describing associations with the microbiome 
between different variables.  
 
Observations based on PCA plots and factors thought to be important in associating with 
microbiome composition, either by PERMANOVA analysis or by defining them a priori, can 
then be substantiated with modeling techniques. Modeling techniques will assess the clustering 
of microbiome points in space in relation to other covariates. The species abundances in a set of 
samples will hardly ever be normally distributed given the presence of multiple zeros for rarer 
microbiome species. Since the data is zero-inflated, there is a need for using either 
transformations or nonparametric statistics. [78] One popular and standard procedure that has 
been in use for long periods of time when analyzing proportional data in ecology is the arcsine 
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square root transformation. [80] The arcsine square root transformation is calculated as two times 
the arcsine of the square root of the proportion. Arcsine square root transformation enables the 
data to be analyzed as normally distributed thus allowing mixed-effect, logistic, and other 
modeling techniques to be applied. [81, 82] 
 
Limited studies on the elderly NH microbiome: potential links to CDI 
Clearly, the microbiome is important for gut health and CDI is all about gut health.  
Furthermore, elderly NH residents are amongst the most important targets of CDI.  Therefore, 
looking at the microbiome of elderly NH patients is a critical part of studying CDI. To date there 
are a very limited number of studies among the elderly in the NH setting evaluating the intestinal 
microbiome. The largest intestinal microbiome investigations involved the ELDERMET cohort 
out of Ireland. The group studying this cohort has reported on correlations between diet, health 
status, and the microbiome composition of 371 elderly subjects living in different settings (NH 
and community). [83] This cohort contained 107 NH elders with longitudinal data and anywhere 
from 1 to 3 samples taken and analyzed. Here they noted microbiota temporal instability in both 
community-dwelling and NH elders, particularly in those with low initial microbiota diversity. 
Other published longitudinal elder metagenomic intestinal investigations have utilized patient 
numbers ranging from 1-20, [84-88] with elderly antibiotic administration and NH microbiome 
based investigations of less than 60 subjects. [55, 87] Important to note is that these 
investigations have not previously explored disease outcomes such as CDI or C. difficile 
colonization among NH elders and associations with the intestinal microbiome composition.  
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What we currently know is that elderly residents in NH care gain a defined population of 
bacteria that are associated with increased frailty. [89] The diet of long-term care elders is 
typically low in fiber with moderate to high fat content. [55] This diet is thought to associate 
with patterns in the intestinal microbiome without a proven cause and effect. [90] It is unclear if 
it is the environment, increased frailty, or diet of residents in NHs that affects the microbiome 
composition towards one of dysbiosis. Various dysbiotic changes in the intestinal microbiota are 
known to increase susceptibility to CDI. [57, 62, 91-93] These dysbiotic microbiomes have been 
shown in animal and human studies but have differed by human patient populations. This 
dysbiosis has a range of potential culprits from both specific bacterial species and metabolic 
functions, such as decreasing levels of secondary bile acids, glucose, and dipeptides to increases 
in primary bile acids and sugar alcohols. [91, 93] A dysbiotic profile for C. difficile colonization, 
especially in NH elderly which are at the highest risk of disease, has not yet been described. 
 
The link noted above between CDI and antibiotics also fits in with this model for the 
microbiome being central to CDI in NH patients.  It is well established that antibiotic exposure is 
a major risk factor for CDI. [4]  Antibiotics have a profound and rapid effect on the gut 
microbiota, with a loss of diversity and a shift in bacterial community composition and function. 
[94] By altering the structure of the gut microbiome, antibiotics alter its function leading to a loss 
in resistance to growth of C. difficile and an increased risk of diarrhea. [62] Not all patients that 
are exposed to C. difficile go on to develop CDI when placed on antibiotics. This raises the 
question of what role the microbiome plays in increasing or decreasing CDI risk after antibiotic 
exposure. Other medications, such as acid reducing medications and corticosteroids, still remain 
controversial over their associations with CDI. Additionally, the effects of these medications in 
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elderly NH residents still remains poorly studied due to the difficulties in NH based research 
outlined above. It is also important to note that associated risks of these medications to CDI may 
differ with regards to C. difficile colonization. In fact, a better understanding of factors, both 
clinical and microbiome based, that increase the risk of C. difficile colonization would give a 
better understanding of this pathogen and novel targets for infection control.  
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2. Specific Aims 
We have set out in a systematic manor to start to address the gaps in our knowledge in C. 
difficile infection and colonization among NH elders. We start off in Chapter 1 by investigating 
the differences between elders from the community and those from the NH setting with regards 
to recurrent CDI. Here we explore if medication exposures from three important classes of 
medications (antibiotics, acid reducing medications, and corticosteroids) have different 
associated risks with recurrent CDI dependent on the home living environment (community or 
nursing home). Next we begin our investigation into the NH elder microbiome. To accomplish 
this we established a cohort of NH elders that in the end involved 91 residents from 4 different 
facilities. Early in this investigation we asked key questions about dysbiosis among NH elders 
reported in Chapter 2. These questions focus on what dysbiotic associations are observed among 
NH elders with regards to advancing age, frailty, malnutrition, and where they live in the facility. 
We had a unique situation in that the first NH facility we enrolled elders was segregated by 
floors with 2 floors in which residents intermingled and 2 others in which they were kept 
separate. Importantly all residents consumed the same diet, thus addressing this important 
confounder. Within this cohort of NH elders we also asked the question about whether there is 
variation in the microbiome composition if stool sampling was performed more frequently (every 
3 days) or less frequently (every 30 days). We also explored whether pathogenic bacterial strains 
(Escherichia coli) are more similar from a phylogenic analysis among residents living on the 
same floor. Finally in Chapter 3 we use the entire cohort of NH elders to investigate: 1) what is 
the prevalence and patterns of C. difficile colonization; 2) do elders living together have more 
similar microbiome profiles; 3) is the phylogeny E. coli grouped by floor and site; and 4) what 
species present in the microbiome can predict the presence of C. difficile in a sample thus 
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defining key bacterial species that together promote C. difficile colonization. The main Aims for 
each chapter are thus: 
	  
• Chapter 1:  To determine if certain medications elders are exposed to have associated risks 
to recurrent CDI that differ by home environment. 
 
• Chapter: To explore the associations of NH environment, frailty, nutritional status, and 
residents’ age with microbiome composition and potential metabolic functions. 
 
• Chapter 3: To examine the colonization patterns seen in NH elders, over time, and to 
identify clinical and microbiome based factors that are associated with colonization status.  
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Figure 1: Test algorithms for the diagnosis of Clostridium difficile infection. (Adapted from[22]) 
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Figure 2: Whole genome shotgun sequencing technique for getting data from a sample 
 
 
Figure 2 Legend: Steps above include: (A) obtaining a sample; (B) extracting the DNA; (C) 
fragmenting the DNA; (D) sequencing the genome; (E) aligning the sequences reads; and (F) 
mapping the reads to a database to obtain taxonomic or gene function data. Databases depicted 
here are Metagenomic Phylogenetic Analysis, MetaPhlAn and Kyoto Encyclopedia of Genes and 
Genomes, KEGG  
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Table 1: Comparison of 16S rRNA to whole genome sequencing techniques 
 16S rRNA Whole Genome Sequencing 
Sequencing target Only the 16S rDNA All genes present 
Diversity Less diversity identified More diversity identified 
Taxonomy quality Better at identification at 
genera or phyla level 
Superior at the species level 
Virus, fungi, and protozoa 
identification 
No Yes 
Data on metabolic pathways No Yes 
Identify bacterial resistance No Yes 
Data <10 gigabytes >>10 gigabytes 
Costs $10-15/sample $100-200/sample 
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Figure 3: Representation of a Permutational multivariate analysis of variance 
(PERMANOVA) analysis of Jaccard distances between two groups A and B on a Principal 
Coordinates Analysis 3D graph 
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CHAPTER 1 
Medication Exposure and the Risk of Recurrent Clostridium difficile Infection by Home 
Environment 
 
ABSTRACT 
Background: It is unclear how medication exposures differ in their association with recurrent 
Clostridium difficile infection (rCDI) between nursing home and community-dwelling elders. 
This study examines these exposures to determine if the risks of rCDI differ by home 
environment.   
 
Methodology: This is a retrospective study of patients 65 years or older with CDI diagnosed by 
symptoms plus positive stool toxin testing from both the academic and community healthcare 
settings. Sociodemographic data, patient characteristics, and medications were extracted from the 
electronic medical record (EMR). We used separate extended Cox models conducted according 
to home environment to identify the association between medication use and risk of rCDI.  
 
Results: Of the 616 CDI treated elders, 24.1% of community-dwelling and 28.1% of nursing 
home elders experienced recurrence within 1 year. Among community-dwelling elders, exposure 
to antibiotics and acid-reducing medications were associated with an increased risk of rCDI (1.6 
and 2.5 times, respectively), however corticosteroid exposure reduced the risk of recurrence by 
39%. Among nursing home elders, the risk of rCDI was 2.9 times higher with acid-reducing and 
5.9 times higher with corticosteroid medication exposures.  
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Conclusion: Recurrent CDI risk was greater for acid-reducing medication than antibiotic use 
after initial CDI treatment, and these risks varied depending on the home environment. 
Additionally, corticosteroid use was associated with increased risk of recurrence in nursing home 
elders but decreased risk in community-dwelling elders. 
  
	   3	  
1. INTRODUCTION  
There has been a worldwide increase in the incidence of Clostridium difficile infection 
(CDI),[4] with annual direct costs associated with the CDI treatment estimated to be nearly $3.4 
billion.[95] Both the prevalence and virulence of this opportunistic pathogen are rising, 
especially among elderly nursing home residents.[5, 40, 47] CDI is common among elders living 
in the nursing home environment, from which a large proportion of new CDI cases are presently 
coming.[96, 97] 
The increasing incidence of recurrent Clostridium difficile infection (rCDI) has been 
alarming with almost a 200% increase from 2001 to 2012.[24] Patients remain vulnerable to 
rCDI for months or even years after initial CDI treatment.[25] Recurrent infection is common, 
occurring in up to 22% of initial cases.[26] The risk factors associated with rCDI are believed to 
be similar to primary CDI although rCDI has been less studied, especially among the elderly. 
Modifiable risk factors include antibiotics, gastric acid medication, and immunosuppressants 
such as corticosteroids.[35, 98, 99] We know that how the initial CDI case is treated may affect 
recurrence, however this has mostly been studied in the hospital setting. Since medication 
treatment after CDI is arguably the most common intervention to reduce rCDI, we focused on 
medications prescribed in both the hospital and outpatient settings.  
Recurrent CDI includes both relapse and reinfection with a new strain.[27] Nursing home 
residents are at particularly high risk of rCDI since exposure to Clostridium difficile in nursing 
home elders is a magnitude of ten times higher than among community-dwelling elders.[100] 
There forth, nursing home elders may be at an increased risk of reinfection compared to 
community-dwelling elders. It is possible that different medication exposures may change the 
associated risk of reinfection after CDI treatment in this environment. Given this large difference 
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in environmental exposure, combined with the higher rates of CDI within a year after CDI 
treatment, we sought to examine the effect of medication use (i.e., antibiotics, antacids, 
corticosteroids) on rCDI and whether it varies by home environment. To accomplish this, we 
followed a cohort of incident CDI patients for 1 year to identify rCDI to determine the 
association of specific medication exposures in a cohort of elders with rCDI, stratified by home 
living status (community-dwelling versus nursing home). This study reports the incidence of 
rCDI among community-dwelling and nursing home elders and the association of rCDI with 
specific medication exposures.  
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2. METHODS 
2.1. Study Setting and Population 
This retrospective cohort study was approved by the institutional review board at the 
University of Massachusetts Medical School. The cohort of CDI positive elders (age ≥ 65 years) 
was identified by using the UMass Memorial Health Care System’s (UMMHC) Theradoc 
Clinical Surveillance Software System (Premier Inc., Charlotte, NC). Using this system we 
constructed a cohort of elderly patients with incident Clostridium difficile enterocolitis between 
2012 and 2014 who initially presented to both academic and community hospital settings. An 
incident case was defined as one positive Clostridium difficile toxin PCR and no evidence of 
CDI in Theradoc or electronic medical record (EMR) within the prior 60 days.[101] We 
confirmed that the incident case was done on a diarrheal stool sample and the patient was treated 
for a CDI. We excluded patients if there were no clinical visits recorded within a six-month 
window after CDI diagnosis or if there was no documentation of initial CDI treatment.  
2.2. Data Collection  
In order to reduce the potential for systematic error and to mitigate bias, we followed 
protocols for the optimal conduct of retrospective studies.[102] Prior to data abstraction 
activities, we a priori defined the pertinent predictor and outcome variables to be collected in a 
standardized manner. Trained abstractors used a standardized collection form to query the EMR 
to obtain longitudinal data pertaining to healthcare visits for up to 12 months after completing 
initial CDI treatment. Demographic data, including age at CDI diagnosis, sex, and race/ethnicity, 
were collected. The EMR was reviewed to obtain data on medication usage and the nature of 
subsequent healthcare visits. We calculated a Charlson comorbidity index (CCI) score to 
characterize the patient’s medical comorbidities.[103, 104] Abstractors worked on different parts 
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of the chart and were blinded to outcome status and patient assignments to reduce information 
bias during patient record review.  
2.3. Classification of Drug Exposures and rCDI Outcomes 
We used the EMR to monitor the prescriptions given to patients during non-CDI related 
visits both within the hospital and outpatient settings at UMMHC. We specifically queried the 
EMR for new antibiotic prescriptions given within 6 months after initial CDI treatment, either 
prevalent corticosteroid use (i.e. treatment for rheumatoid arthritis) or incident corticosteroid use 
within 6 months (i.e. treatment for asthma exacerbation), and both prevalent and incident acid-
reducing medication use (within 6 months after CDI), which included both proton pump 
inhibitors (PPIs) and H2 blocker medications. Antibiotic prescriptions taken for the treatment of 
CDI were not included as an antibiotic exposure (e.g. metronidazole or oral vancomycin). Given 
immunological senescence that accompanies age may be a major risk factor for rCDI[105] and 
this may be exacerbated by use of steroids in older adults, we included steroids in the drug 
exposures we monitored for after CDI treatment. Only after all study information was collected 
for all participants were rCDI outcome status assignments made by two independent physician 
reviewers (JH, EB). Where there was a disagreement between the reviewers a third independent 
adjudicator (XW) made the final determination.  
2.4. Data Analysis 
We used Chi-square tests to compare categorical variables, and the student’s t-test for 
continuous variables, between patients with rCDI and those that were censored. Since the Cox 
model assumes that each covariate has a multiplicative effect on the hazards function that is 
constant over time, we tested this hypothesis among our variables of interest graphically with 
log-log plots of survival and on the basis of Schoenfeld residuals. After examining the 
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proportional hazards assumption for Cox proportional hazards model, we decided to use an 
extended Cox model which allowed for time-varying exposures[106] to identify association of 
predictors of interest with the outcome of rCDI. Clinically important factors included antibiotic 
exposure within 6 months of initial CDI treatment, acid-reducing medication use, and 
corticosteroids as the main variables of interest, in addition to patient demographics (including 
age, gender, and race), patient medical comorbidities (CCI score), and patient residence (nursing 
home versus community). The final adjusted model included both clinically important factors a 
priori and variables associated with the outcome at p<.10 in unadjusted analysis. Kaplan-Meier 
survival analysis was used to determine time to incident rCDI diagnosis. The logrank test was 
used to compare survival curves of time to incident rCDI diagnosis. Separate extended Cox 
model analyses were conducted according to home environment. Significance was set at .05 for 
all analysis. 
We utilized multiple-imputation to address missing data in our data set, assuming data 
were missing at random. We conducted sensitivity analyses to examine the effect of patients lost 
to follow-up. Using best-case and worst-case scenarios, we constructed a logistic model 
predicting rCDI using initial patient demographics and treatment conditions. The models with 
the patients that were lost to follow-up were coded as either none having rCDI or all having 
rCDI. We used Stata, version 13.1 for all analyses (StataCorp LP, College Station, TX). 
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3. RESULTS 
3.1. Characteristics of the Study Subjects 
During the 3-year study period from 2012 – 2014, there were 863 incident cases of CDI. 
We excluded 84 (9.7%) patients who died during the initial index visit, 125 (14.5%) patients 
without follow-up EMR data, and 38 (4.4%) patients who only had EMR visit data during the 
initial treatment phase. The final cohort included 616 elders. Within the following year, 161 
(26.1%) patients experienced recurrent CDI. The prevalence of rCDI among community-
dwelling elders was 24.1% and among nursing home residents was 28.2%.  
3.2. Risk Factors for Incident rCDI 
Among patients with and without rCDI, there were no differences in baseline 
demographics or medical history with the exception of a higher prevalence of prior 6 month 
history of CDI treatment among those with rCDI (Table 1.1). Patients with rCDI had higher 
prevalence of exposure to an antibiotic within 6 months after initial treatment and higher 
prevalence of exposure to acid-reducing medications. The number of corticosteroid exposure 
events was similar between the two groups.  
Extended Cox model analysis found a history of CDI within the previous 6 months, 
antibiotic and acid-reducing medication exposures to be significantly associated with reduced 
time to rCDI after adjusting for age, gender, home environment (nursing home versus 
community), medical comorbidities, and corticosteroid use. In adjusted analysis, antibiotic 
exposure within 6 months after completion of CDI treatment yielded an adjusted hazard ratio 
(aHR) of 2.62 (95% confidence interval [CI], 1.44 to 4.76) while acid-reducing medication 
exposure had an aHR of 4.68 (95% CI, 2.83 to 7.73). A history of CDI prior to the initial CDI 
episode as entrance into this cohort had an aHR of 1.52 (95% CI, 1.04 to 2.20).  The significance 
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of demographic and treatment variables did not change in our sensitivity analysis using best-case 
and worst-case scenarios when including those patients lost to follow-up. 
3.3. Risk Factors Stratified by Living Environment 
We stratified our analysis by home environment to test the hypothesis that medication 
exposure carried different risk profiles for rCDI depending on whether the patient lived in a 
nursing home or in the community. Community-dwelling and nursing home elders did not 
significantly differ by age, gender, race, CCI score, or previous history of CDI nor did they differ 
in their rates of exposure to antibiotics, acid-reducing medications, or corticosteroids. We 
observed higher levels of exposure to antibiotics among those with rCDI compared to those 
without rCDI in the community (58.3% versus 28.5%, p<0.001) and in the nursing home (50.0% 
versus 30.1%, p=0.038). Similarly, elders with rCDI had greater exposure to acid-reducing 
medications compared to those without rCDI in the community (62.9% versus 30.8%, p<0.001) 
and nursing home (72.2% versus 24.1%, p<0.001). With regards to corticosteroid exposure, 
elders with rCDI had similar levels of exposure to elders without rCDI in the community (17.4% 
versus 17.4%, p=.98), but a higher level of exposure in the nursing home setting (19.4% versus 
8.4%, p=0.045).  
Stratifying the extended Cox model by home environment resulted in different HR for 
each medication exposure (Table 1.2).  Among community-dwelling elders, exposure to 
antibiotics and acid-reducing medications was associated with an increased risk of rCDI (63% 
and 2.5 times higher than in those not exposed, respectfully), however corticosteroid exposure 
reduced the risk of recurrence by 39% (Table 1.2). Among nursing home residents, the HR for 
antibiotic exposure was not significant; however, the HR was 2.9 times higher with acid-
reducing medication exposure and 5.9 times higher when exposed to corticosteroids. Medication 
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exposures demonstrated in the Kaplan-Meier survival curves varied significantly stratified by 
home environment (Figure 1.1).  
4. DISCUSSION 
Elders living in a nursing home had slightly higher, but non-significant, occurrence of 
rCDI. Medication exposures studied here were associated with an increased risk of rCDI 
however this associated risk differed by home environment. In the nursing home, the risk of 
rCDI was increased with exposure to acid-reducing medication and corticosteroids. In the 
community, antibiotic exposure within the first 6 months after treatment for CDI was associated 
with an increased risk of rCDI while corticosteroid exposure in this group was associated with a 
reduced rCDI risk. Our findings add to the literature by highlighting the possible importance of 
the patient’s home environment when it comes to medication exposure and risk of rCDI. We feel 
these findings underscore the importance for clinicians of reducing any antibiotic or acid-
reducing medication exposure among the elderly after CDI treatment, especially among NH 
residents.  
Our findings of an association between medication exposures and an increased risk of 
rCDI are consistent with the literature. While the mechanism for recurrence is unknown, the 
most common risk factors include the use of antibiotics and gastric acid-suppressive therapy.[26, 
32] Acid-reducing medications that include both PPIs and H2 blockers are well known to be 
associated with increased risk of CDI.[107] The exact relationship between acid-reducing 
medication use and incident rCDI remains elusive with no causative pathway having yet been 
demonstrated.[29, 108] Recent attention has turned to the human microbiome as a novel vehicle 
for predicting and preventing disease. The human colon harbors a vast array of microbes (the gut 
microbiota) that critically influence human physiology and have long been known to influence 
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human health and disease.[52] It has been observed that patients taking a PPI have changes in 
their microbiome that are in line with known changes that predispose patients to CDI and can 
potentially explain the increased risk of CDI in PPI users.[109] 
The role of corticosteroids is much less clear because they have been shown to both 
increase and decrease the risk of incidence of and mortality from CDI.[36-39] Patients with 
chronic steroid use have been shown to have a threefold increased risk of CDI.[110] This, 
however, has been balanced with reports showing that when corticosteroids are used 
intermittently it can reduce the risk of CDI.[37] Here, we have demonstrated that corticosteroid 
exposure is associated with a reduction in the risk of rCDI in community-dwelling elders, 
however it is associated with an increased risk in nursing home elders. Corticosteroids 
significantly alter the microbiome of the intestine,[111] which might also lead to predisposing a 
patient to rCDI. Our findings of the associated increased risk of rCDI with corticosteroid 
exposure in NH residents needs further exploration, however from a clinical standpoint, avoiding 
corticosteroid use in NH elders after CDI treatment could possibly reduce the risk of rCDI.  
Recurrent CDI includes both relapse of CDI with the same strain and reinfection that is a 
result of a new strain, which is clinically indistinguishable.[27] We believe that the role of the 
home environment in the different observed associations of rCDI to these medications may be 
due to the level of exposure to C. difficile spores in the environment causing reinfection. Rates of 
C. difficile present in the stool of elders are the highest in nursing homes with 20% to 50% of 
residents affected compared with 1.6% in the general community and 9.5% in the outpatient 
setting.[53, 58] Since corticosteroids and acid-reducing medications significantly alter the 
microbiome of the intestine, this might allow for C. difficile spores present in the environment to 
take hold and cause a recurrence of CDI within a year after initial CDI treatment.  
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4.1. Strengths and Limitations 
One limitation of this current study is the retrospective design. Since patients needed 
follow-up data in the EMR to confirm recurrence, there is a possibility of misclassification of the 
outcome. This retrospective study did exclude some patients after the date of CDI diagnosis thus 
it is subject to a number of biases, most notably selection bias. Since we excluded patients that 
died before initial treatment completion, due to the fact that there was not a possibility for 
recurrence given the death, we may have introduced selection bias. However, there were similar 
numbers of deaths among each home environment group. To help mitigate this bias we 
developed a priori inclusion criteria. Additionally, medication exposures may have varied in 
magnitude given whether a patient took the prescription as written or at all. In addition, we 
included both incident and prevalent corticosteroid and acid-reducing medication use if a 
resident was taking the medication during entrance to the cohort and maintained on this 
medication throughout the study (i.e. corticosteroid treatment for rheumatoid arthritis). The type 
of corticosteroid exposure (chronic or intermittent) has been reported to differ with an associated 
increased risk of rCDI with intermittent use but a reduced risk of rCDI with chronic use.[36-39]  
Interestingly, all nursing home elders with corticosteroid exposures were incident. Finally, the 
study is limited by the small number of participants who were living in a nursing home. Further 
study in a larger population is warranted. 
4.2. Conclusions 
In conclusion, this paper’s findings highlight differences in the associated risks of rCDI 
with antibiotic and acid-reducing medication use after initial CDI treatment that vary depending 
on the home environment. Avoiding both of these medications in the elderly patient in the 6 
months after recovering from CDI may reduce that patient’s risk of recurrence. Additionally, we 
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found that corticosteroid use was associated with an increased risk in nursing home elders and 
decreased risk in community-dwelling elders for rCDI, adding a further dimension to the 
controversy over steroid use after CDI. Studies are needed to confirm these finding of increased 
risk with corticosteroid use and also to determine what affects corticosteroids are having on the 
patient or their microbiome to increase this risk. Until that time, reducing corticosteroid exposure 
in nursing home patients recovering from a CDI may reduce the subsequent risk of recurrence.    
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5. TABLES AND FIGURES 
Table 1.1: Characteristics of the Baseline Population of 616 Older Adults at Risk for 
Recurrent Clostridium difficile Infectiona 
Baseline Characteristics 
 No rCDI 
(n=455) 
rCDI 
(n=161) 
p value 
Age (SD) 76.5 (8.0) 76.7 (8.4) 0.39 
Female 262 (57.6) 99 (61.5) 0.39 
White 413 (90.8) 141 (87.6) 0.25 
Black 13 (2.9) 6 (3.7) 0.58 
Hispanic 21 (4.6) 8 (5.0) 0.86 
Nursing Home  83 (18.2) 36 (22.4) 0.26 
CCI Score (SD) 2.7 (2.2) 2.7 (2.3) 0.60 
Hx CDI    
< 6 months 61 (13.5) 61 (37.9) 0.001 
> 6 months 28 (6.2) 39 (24.2) 0.07 
Medication Exposures 
Antibiotics  132 (29.0) 94 (58.4) <0.001 
Acid Reducing  139 (30.5) 105 (65.2) <0.001 
Steroids 72 (15.8) 30 (18.6) 0.41 
rCDI, recurrent Clostridium difficile Infection; SD, standard deviation; CCI, Charlson 
comorbidity index; Hx CDI, previous history of Clostridium difficile infection 
a Data are presented as n (percentage) unless otherwise indicated 
 
Table 1.2: Stratified Extended Cox Regression Model for Community-dwelling and 
Nursing Home Eldersa 
 Community Elders NH Elders 
 Hazard Ratio p value Hazard Ratio p value 
CCI Score 0.80 (0.71-0.90) <0.001 1.12 (0.95-1.33) 0.18 
Hx CDI <6 mo 1.46 (0.97-2.20) 0.07 2.49 (1.03-6.01) 0.043 
Antibiotics 1.63 (1.00-2.67) 0.05 1.12 (0.47-2.68) 0.80 
Acid Reducing 2.51 (1.72-3.78) <0.001 2.98 (1.12-7.92) 0.029 
Steroid 0.61 (0.38-0.98) 0.039 5.90 (1.66-20.98) 0.006 
CCI, Charlson comorbidity index; Hx CDI, previous history of Clostridium difficile infection 
a Data are presented as HR (95% confidence intervals) 
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Figure 1.1 Kaplan-Meier survival curves of time to incident diagnosis of recurrent 
Clostridium difficile Infection (rCDI) in patients with and without medication exposures 
stratified by n=497 community-dwelling (a) and n=119 nursing home (b) elders. 
 
  
 
a 
b 
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CHAPTER 2 
The Nursing Home Elder Microbiome Stability and Associations with Age, Frailty, 
Nutrition, and Physical Location 
ABSTRACT 
Background: The microbiome from nursing home (NH) residents is marked by a loss in diversity 
that is associated with increased frailty. Our objective was to explore the associations of NH 
environment, frailty, nutritional status, and residents’ age with microbiome composition and 
potential metabolic function.  
 
Methodology:  We conducted a prospective longitudinal cohort study of 23 residents 65 years or 
older from one NH that had 4 floors: 2 separate medical-intensive floors, and 2 floors with active 
elders over a 4 month period of time. Residents’ were assessed using the Mini Nutritional 
Assessment tool and Clinical Frailty Scale. Bacterial composition and metabolic potential of 
resident stool samples was determined by metagenomic sequencing. We performed traditional 
unsupervised correspondence analysis and linear-mixed effect modeling regression to assess the 
bacteria and functional pathways significantly affected by age, clinical frailty, malnutrition, and 
floor location of residence. .  
 
Results: Nursing home resident microbiomes demonstrated temporal stability (PERMANOVA 
p=0.001) and differing dysbiotic associations with increasing age, frailty, and malnutrition 
scores. In older residents, the abundance of microbiota-encoded genes and pathways related to 
essential amino acid, nitrogenous base, and vitamin B production declined. With increasing 
frailty, residents had lower abundances of butyrate producing organisms, which are associated 
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with increased health, and higher abundances of known dysbiotic species. Butyrate producing 
organisms declined and dysbiotic bacterial species increased with increasing malnutrition scores. 
Finally, the microbiome of residents living in proximity shared similar species as demonstrated 
by the phylogenetic tree for E. coli, where residents on the same floor had similar strains.   
 
Conclusion: These findings support that a signature “nursing home” microbiota may exist that is 
affected by the residents age, frailty, nutritional status and physical location. 
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1. INTRODUCTION 
In the US, nursing homes (NHs) provide custodial care to older adults that need both 
medical and non-medical assistance, such as support for activities of daily living. These NH 
elders are grouped together and share a diet that is typically low in fiber with moderate to high 
fat content [55]. Residents living in NHs suffer from a high prevalence of Clostridium difficile 
and multi-drug resistant organisms (MDROs) that both colonize the intestinal track and cause 
active disease. The prevalence of these pathogens colonizing the gut is so high that the NH is 
now considered a reservoir for introducing these pathogens into other healthcare settings [112, 
113]. Unrelated individuals living together have more similar gut bacterial communities 
compared to individuals living in other households, suggesting a shared environment affects the 
similarity of the fecal microbiome [114]. The similarities of NH elders microbiome has not 
previously been explored, warranting further research to better understand the factors leading to 
the development of the NH as a reservoir for MDROs for the community at large [115].  
A healthy, diverse intestinal microbiome interacts positively with the host immune 
system and contributes to pathogen resistance [116]. Older adults that enter a NH experience an 
overall decline in intestinal microbiome function [117] and a significant loss in diversity when 
compared to community-dwelling elders [55]. Elders from NHs differ from community-dwelling 
counterparts in their microbiome composition, with higher proportions of the phylum 
Bacteroidetes compared to phylum Firmicutes and lower genus Coprococcus and Roseburia 
abundances [55]. Most previous elder microbiome investigations have focused on comparing 
community-dwelling to NH elders. These studies have concluded that NH residents gain a 
nursing home-associated microbiome that is mostly a result of the NH provided diet along with 
the increasing individual frailty associated with elders that need NH services [89]. Given the 
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variability in diets of elders living in NH or community-dwelling environments included in these 
studies, their conclusions have strongly highlighted the associations between diet and 
microbiome composition. This still leaves ambiguity as to what occurs to a NH resident 
microbiome as they age and their health status evolves with increasing frailty and malnutrition.  
Elders are commonly grouped together in sections of the NH by medical or mental (i.e. 
dementia units) needs. Geographical location is known to influence the microbiome composition, 
however the influence diet versus physical location plays is not well understood [118]. A better 
understanding of environmental influences on human microbial communities could be an 
important factor to consider when understanding disease etiologies especially among vulnerable 
NH elders. Accordingly, the “nursing home microbiota” remains poorly defined especially when 
it comes to other factors besides frailty and diet that may influence its composition such as 
increasing age, malnutrition, or physical location. In addition, the complex interplay between 
patient-level and environmental (facility)-level factors and their influence on the microbiome in 
this vulnerable population is poorly understood.  
Accordingly, we set out to follow a cohort of elders from one NH to investigate the 
associations of age, frailty, malnutrition and physical location and observed dysbiosis and the 
stability of the microbiome over time. We performed these observations among NH elders 
consuming the same diet, however they lived in separate sections of the same NH facility with 
specific floors being isolated from others. Our findings contribute to the understanding of how 
patient-level factors, such as age, frailty, and malnutrition level, influence the microbiota 
composition while adding novel discoveries as to the associations that facility-level factors (i.e. 
floor location) have with microbiome composition.  
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2. METHODS 
2.1. Study Setting and Population 
This prospective cohort study was approved by the institutional review board at the 
University of Massachusetts Medical School. This cohort is NH residents ≥65 years of age who 
lived in one NH facility that contained 4 different floors. The 3rd floor was the facility’s locked 
dementia unit where residents were not allowed off the floor unless for issues regarding medical 
care. The next floor (4th floor) was termed the medical care unit housing residents with chronic 
medical issues requiring a higher level of nursing care, their food and care limited to this 
location. The 5th and 6th floors housed higher functioning long-term care residents who all ate 
and engaged in activities in one central location. They were also allowed to travel off of the floor 
frequently into the community. We approached residents across all floors who had been living at 
that facility for ≥1 month and did not have any diarrheal illness or antimicrobial exposure within 
the preceding 4 weeks. All residents throughout the facility followed the same low-fiber diet 
across all floors prepared in one central kitchen that is typical for a nursing home diet. No 
patients suffered from dysphagia or had a feeding tube.  
2.2. Data Collection  
Data were collected over a 4 month period of time. We conducted baseline and end of 
study medical record abstraction for factors associated with key study outcomes. These factors 
included age, nutritional status, comorbidities, use of proton pump inhibitors, and frailty [55]. 
Prior history of hospitalizations, antibiotic exposures in the past year, and histories of 
Clostridium difficile infection or urinary tract infections were collected from the medical record. 
The key outcome variables were age, frailty status, malnutrition status and floor location. We 
obtained age, sex, race, and length of NH stay from the medical record. We categorized residents 
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into 4 age categories for analysis: 1) 65 to 74; 2) 75 to 84; 3) 85 to 94; and 4) ≥95 years of age. 
This was done to show relations with decade increases in age rather than by year. Frailty was 
categorized according to the validated and widely utilized Canadian Study of Health and Aging’s 
(CSHA) 7-point Clinical Frailty Scale [119]. This has been previously validated in 
demonstrating signatures of frailty in the gut microbiota [120, 121]. We assessed nutritional 
status using the Mini Nutritional Assessment (MNA) tool [122-124]. Residents were categorized 
as normal, at risk, or malnourished based on the MNA survey administered by trained research 
staff to the residents or the nurse caring for the resident if mentally impaired. All residents were 
enrolled for a total of 4 months in which we monitored for any changes to their care.  
2.3. Sample Collection and Processing 
We collected 4 monthly stool samples from each resident. Additionally, from 6 residents 
we collected samples every 3 days for 2 weeks and then monthly for 4 months to investigate 
whether the microbiome varied over short or long sampling intervals. DNA was extracted from 
samples using the PowerMagTM Soil DNA Isolation Kit on an epMotion 5075 TMX liquid 
handling workstation according to manufacture protocols (MO BIO Laboratories, #27100-4-EP). 
Sequencing libraries were constructed using the Nextera XT DNA Library Prep Kit (Illumina, 
Inc., #FC-131-1096) and sequenced on a NextSeq 500 Sequencing System as 2 x 150 base pair-
end reads. 
2.4. Sequence Processing and Analysis 
Shotgun metagenomic reads were first trimmed and filtered of host contamination using 
Trimmomatic [125] and Bowtie2 [126] as part of the KneadData pipeline 
(https://bitbucket.org/biobakery/kneaddata). Reads were then profiled for microbial species 
abundances using Metaphlan2 [127] and for abundance of Uniref genes, KEGG orthologues, and 
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of the corresponding functional pathways (Metacyc pathways, KEGG pathways, and KEGG 
modules) using the software pipeline HUMAnN2 [128] and in-house written scripts (available 
upon request). Normalized taxonomic, gene, and pathway abundances were then used for 
downstream statistical analysis in R (see below). Strain-level analysis of Escherichia coli present 
in metagenomic samples was performed using StrainPhlAn [129]. Reads were mapped against 
the MetaPhlan2 clade-specific marker gene database [130].  Reconstructed E.coli-specific 
consensus markers were derived from the mapping data. The reconstructed markers were then 
used to build a phylogeny of the strains. The tools cited, in turn, depend upon the following—for 
KneadData: Trimmomatic [125], Bowtie2 [131], SAMtools (https://github.com/samtools/); for 
StrainPhlan: MetaPhlan2 [130], MUSCLE [132], RAxML [133], blastn [134]. The phylogenetic 
tree was visualized with FigTree (http://tree.bio.ed.ac.uk/software/figtree/) 
2.5. Data Analysis 
We performed traditional unsupervised correspondence analysis (NMDS and 
unsupervised hierarchical clustering) to first determine samples similarity with respect to the 
above covariates of interest. Permutation Multivariate Analysis of Variance (PERMANOVA) 
was performed to evaluate inter- vs intra-individual variability in bacterial abundance. To 
determine the contribution of each covariate to changes in microbiome composition (including 
microbial and functional pathways abundances) we performed linear-mixed effect modeling 
regression after arcsine square root transformation [81] using the R package lme4. P-values were 
calculated using a Kenward-Roger Degrees of Freedom Approximation and the returned t-value 
from the regression modeling. Covariates with  p < 0.05 were retained and used for downstream 
visualization and data interpretation.  
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3. RESULTS 
3.1. Characteristics of the Study Subjects by Floor Location 
Over a six-month period we enrolled and followed 23 NH elders collecting monthly 
samples for a total of 4 months. Residents of the medical floor (4th floor) and dementia unit (3rd 
floor) had higher frailty and malnutrition scores than those on the 5th and 6th floors (Table 2.1). 
Residents on the 4th floor were older with an average age of 96.4. There were no differences in 
how long the resident had been living on that floor (length of stay) nor with regards to CCI score. 
No residents were exposed to antimicrobials or hospitalized during the study period. The last 
antimicrobial exposure occurred three months’ prior to enrollment in only one subject.  
3.2. The Individual NH Microbiome Demonstrates Stability Over Short and Long Time-
Interval Observations 
There were 6 residents for whom we collected samples every 3 days for 2 weeks and then 
monthly afterwards for 4 months, resulting in a total of 10 samples per resident. We had one 
resident in which we were only able to obtain 8 samples with 2 missed time points during the 2-
week sampling time period. The average age of this group was 82.7 (9.2) years, all living on the 
5th and 6th floors with an average frailty score of 5.2 (0.4) and malnutrition score of 0.2 (0.4). 
None of these residents had any changes in medications or healthcare exposure over the study 
period. Microbiota compositional differences were greater between individuals than within 
individuals demonstrating fecal microbiota stability in NH elders (PERMANOVA – Jaccard 
distance p=0.001; Figure 2.1a). The microbiome composition between individuals varied as 
demonstrated at the order level in Figure 2.1b. These data indicate that, for long-stay NH 
residents, both 3-day and 30-day collection frequencies exhibit similar microbiome variation 
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within an individual, which remains stable over time as long as there are not any changes to their 
diet or changes in medications. 
3.3. Distance Measures Demonstrate Grouping Patterns by Age, Frailty, and Malnutrition 
We explored beta-diversity by principal component analysis (PCA) using Jaccard 
distances for a measure of community species dissimilarity among combinations of malnutrition 
scores, frailty scores, age categories and floor locations in Figure 2.2. Microbiota compositional 
differences were greater between the covariates of  malnutrition scores, frailty scores, age 
categories and floor location than within them with a PERMANOVA – Jaccard distance p<0.001 
for each of the covariates. First, with regards to age and frailty, we note not only a pattern of 
shifting of composition towards the right as the age category increases but also a clustering of 
groups by frailty score, Figure 2.2a. Comparing malnutrition and frailty, we see a similar pattern 
of shifting composition towards the top right. As malnutrition scores increased they maintain a 
clustering by frailty score, Figure 2.2b. However, when we explore PCA analysis by floor 
location, any discernable pattern seems to be mixed with floors 3 and 4 clustered towards the 
middle surrounded by resident samples from floors 5 and 6, Figure 2.2c. There seemed to be a 
difference between floors when residents from floors 5 and 6 were combined as if they were on 
the same floor. We explored combinations of each of the variables represented in Figure 2.2a-c. 
with ellipses that represent 75% confidence intervals. These ellipses demonstrate clustering of 
combinations of the grouping categorical variables. If there were less than 4 samples per 
grouping, we omitted the ellipses. From these groupings, certain patterns emerged. For example, 
in Figure 2.2a. residents in age category 3 shifted in microbiome composition to the right as 
their frailty score increases from 3 to 6. From this analysis, we noted clustering among the 
variables of malnutrition, frailty and age without any specific pattern to floor location, 
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suggesting the overall microbiome composition did not correlate with location as it did to 
malnutrition, frailty and age.  
3.4. Mixed Effect Modeling Demonstrated Age, Malnutrition, Frailty, and Location 
Affected Bacterial Species Composition and Functional Pathways 
After unsupervised correspondence analysis, we performed linear-mixed effect modeling 
regression to determine the bacterial species and contributed functional pathways that were 
significantly affected by the covariates of interest. Briefly, after arctangent-square root 
transformation of microbial species (and pathways) abundances, we performed linear-mixed 
effect modeling regression. We fit the model Abundance ~ 1 + Age + Malnutrition + Floor + 
Frailty + (1 | ID), where Age, Malnutrition, Floor and Frailty are the fixed effect and ID 
represent the random effect. Using this approach, we decoupled the effect of each of the modeled 
covariates towards the microbial (or pathways) abundance and assessed each covariate’s 
statistical significance independently. Row-normalized abundances of significant Species and 
KEGG Pathways are displayed as hierarchical clustered heat-maps in Figure 2.3a and Figure 
2.3b. The Species and KEGG Pathways depicted in Figure 2.3 are statistically significant for at 
least one of the model fixed effects.   
3.5. Dysbiosis with Increasing Age in both Bacterial Species and Metabolic Pathways 
We observed correlation of species and pathway abundances with increasing age. 
Akkermansia muciniphila, a mucin-degrading bacterium known to decrease in the elderly [135], 
was significantly decreased in residents in age category 3 (p=0.018) and Ruminococcus bromii, a 
keystone species in degradation of starch, was elevated in age category 2 (p=0.012) and then 
decreased in older age categories. The bacterial species Ruminococcus gnavus, which has been 
associated with a dysbiotic microbiota [136], was more abundant in age category 2 (0.003) and 
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lower in older residents with the lowest abundances in age category 4 (0.015). Several bacterial 
species known to be butyrate producers [137] were elevated in older adults.  Butyrate is known 
to contribute to the maintenance of the gut barrier functions, and has both immunomodulatory 
and anti-inflammatory properties [138]. Butyrate producing Eubacterium siraeum was 
significantly elevated in age category 4 (p=0.004) and Roseburia intestinalis was elevated in age 
category 2 (p= 0.012), 3 (p= 0.002), and 4 (p= 0.016). 
Metabolic pathways involved in essential amino acid biosynthesis and metabolism were 
higher in younger residents and decreased over the subsequent age categories, Figure 2.4. This 
involved cysteine and methionine metabolism (ko00270; p= 0.017), histidine metabolism 
(ko00340; p= 0.020), valine, leucine and isoleucine biosynthesis (ko00290; p= 0.005), and lysine 
biosynthesis (ko00300; p< 0.001). In addition, nitrogenous base metabolism also decreased with 
increasing age as purine and pyrimidine metabolism decreased over age categories 2 (ko00230 
and ko00240; p = 0.004, 0.010) and 3 (0.028, 0.010). Finally, vitamin metabolism was also lower 
in older residents. Vitamin B5, pantothenate and CoA biosynthesis, decreased in age categories 2 
(ko00770; p= 0.013) and 3 (p= 0.004), and vitamin B1 thiamine metabolism was lowest in age 
category 3 (ko00730; p=0.022). Combined with the species data, these results indicate that the 
dysbiosis associated with aging included decreases in mucin and starch degradation, essential 
amino acid synthesis, and decreases in nitrogenous base and vitamin synthesis.  
In conjunction with the observed butyrate-producing species being of higher abundance 
in older residents, we also noted that butyrate metabolism also rose with increasing age and was 
significantly elevated in age category 3 (ko00650; p= 0.031). Pyruvate metabolism increased 
over the age categories and was highest in age category 3 (ko00620; p= 0.019) while CoA 
biosynthesis increased in age category 2 (ko00770; p= 0.013) and 3 (p= 0.004). Butyrate is 
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synthesized via pyruvate and acetyl-coenzyme A (CoA) [139]. Taken together this signifies that 
butyrate producing organisms and butyrate production, a sign of increased intestinal health, 
increased with age.  
3.6. Dysbiotic Patterns with Increasing Frailty 
After adjusting for age, malnutrition and floor location, residents with lower frailty scores 
had higher abundances of butyrate-producing organisms in Figure 2.5, notably members of the 
Clostridium cluster XIVa [140] as well as Lachnospiraceae bacterium 5_1_63FAA [141]. 
Conversely the bacterial species R. gnavus, which is associated with a dysbiotic microbiota 
[136], was higher in residents with higher frailty scores peaking at a clinical frailty score of 7 
(p=0.009). From a metabolic potential standpoint, residents with higher clinical frailty scores had 
higher abundances of lipopolysaccharide (LPS) biosynthesis (ko00540; p=0.043), peptidoglycan 
(PGN) biosynthesis (ko00550; p= 0.029) and sphingolipid metabolism (ko00600; p=0.014). The 
observed dysbiosis with increasing frailty included lower butyrate-producing organisms with 
increases in LPS and PGN biosynthesis as well as sphingolipid metabolism. Alterations in LPS, 
PGN, and sphingolipid synthesis and metabolism have all been linked to increased bowel 
inflammation [142, 143]. 
3.7. Malnutrition’s Association with Dysbiotic and Opportunistic Organisms 
For residents who were either at risk of malnutrition or scored as malnourished, we noted 
trends of higher abundances of organisms associated with a dysbiotic microbiome. We found 
increased abundances of Citrobacter freundii in malnourished residents (p=0.020). These 
bacteria serve as opportunistic and super-infectious agents in immunocompetent and 
compromised patients [144]. Additionally, Enterococcus faecalis, which causes life-threatening 
hospital associated infections in humans such as sepsis, urinary tract infections and meningitis 
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[145], was also elevated in malnourished residents (p=0.014). Similar to increasing frailty, the 
bacterial dysbiotic species R. gnavus, was lowest in non-malnourished residents (<0.001). 
Finally, the butyrate producing organism R. intestinalis, was less abundant in both residents at 
risk of malnutrition (p<0.001) and those that were malnourished (p<0.001). Subdoligranulum, a 
spore-forming butyrate producer [146] was also reduced in the malnourished (p=0.008). From a 
metabolic standpoint PGN biosynthesis was noted to be elevated in malnourished residents 
(ko00550; p= 0.008). Malnutrition associated with opportunistic dysbiotic bacterial species as 
well as lower butyrate producing organisms with increased inflammation was associated with 
higher PGN biosynthesis levels.  
3.8. Residents from the Same Location Share Similar Bacterial Organisms 
Specific bacterial species were found to be more abundant among residents located on 
different floors, Figure 2.6a-e. Residents living on the medical floor (4th floor) had higher 
abundances of the dysbiotic bacterial species, R. gnavus (p<0.001), and organisms that can cause 
opportunistic infections such as Clostridium bolteae [147, 148] (p=0.038). Other bacterial 
species, such as Coprococcus catus and Eubacterium ventriosum were of higher abundances in 
residents on the dementia unit (3rd floor) in comparison to the residents on other floors. Not 
much is known of these two bacterial species. The anti-inflammatory Lachnospiraceae bacterium 
8_1_57FAA [149] was of greater abundance in residents living on floors with higher functioning 
elders (5th floor; p=0.015 and 6th floor; p=0.006). Lactobacillus reuteri, and anti-inflammatory 
bacterial species [150], was also higher in residents on the 5th and 6th floors (p=0.003 and 
p=0.006). Taking all of these associations together, it points towards elderly residents that live 
together share specific bacterial species.   
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Finally, we wondered if residents shared genetically similar strains of bacteria. Observing 
that strains are shared between NH residents could have implications with respect to 
transmission of infections. Thus, we constructed the genetic relationship of Escherichia coli 
carried by seven individual residents from metagenomic sequence data, Figure 2.7. Escherichia 
coli was chosen for strain-level analysis due to it being both a common bacterial species that 
colonizes the intestines and is a species known to cause disease (e.g., urinary tract infections). 
The phylogenic tree demonstrates that ambulatory residents on the 5th and 6th floors had E. coli 
strains sharing more similar phylogenetic relationships than patients on the 4th floor (medical 
floor). Interestingly two of the resident E. coli phylogeny intermingle (yellow and pink, Figure 
2.7), suggesting a high-degree of strain similarity. These data suggest that residents that share 
common living areas had genetically related Escherichia coli strains compared to other residents 
living in a separate area of the same facility that did not intermingle. We also performed strain-
level analysis on other common commensal bacterial species but did not note any such floor 
association patterns. 
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4. DISCUSSION 
Nursing home residents demonstrated different dysbiotic associations with increasing 
age, frailty, and malnutrition scores. As the age of residents increased, the abundance of 
microbiota-encoded genes and pathways related to essential amino acid, nitrogenous base, and 
vitamin B production declined. With increasing frailty, residents had lower abundances of 
butyrate-producing organisms, higher abundances of known dysbiotic species, higher LPS and 
PGN biosynthesis, and higher sphingolipid metabolism. Alterations in LPS, PGN, and 
sphingolipid biosynthesis and metabolism have all been linked to increased bowel inflammation 
[142, 143]. Among residents who were at risk of or were malnourished, butyrate producing 
organisms declined and opportunistic and dysbiotic bacterial species increased along with PGN 
biosynthesis. Interestingly, when looking at physical location within the nursing home, residents 
living together shared similar bacterial species and had similar E. coli phylogeny. Taken 
together, this suggests that the “nursing home” microbiota is influenced by resident age, frailty, 
nutritional status and physical location. 
With increasing resident age, we found that bacterial species previously observed to 
decline with age were reduced. Specifically, A. muciniphila and R. bromii decline as a likely 
result of changes in the diet of older adults. This dietary change favors growth of bacteria that are 
able to degrade mucins [135, 151] and metabolizing dietary plant polysaccharides [152]. 
Additionally, R. gnavus, a species known to decrease with age [153], was higher in residents 
aged 65-74 and exhibited lowest abundances in those 95 and older. In older NH residents, we 
also observed a dysbiotic decrease of metabolic pathways involved in essential amino acid, 
nucleotide, and vitamin B biosynthesis. Aging has been associated with a progressive loss of 
muscle mass (sarcopenia) which is linked to lower availability of essential amino acid [154, 
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155]. Purine and pyrimidine nucleotide biosynthesis modules are known to be globally decreased 
in inflammatory bowel diseases (IBD) patients [156] as well as the vitamin B complex [157]. 
Taken together, these metabolic pathways reflect an age-specific dysbiosis specific to chronic 
intestinal inflammation seen in the elderly.  
With increasing frailty or malnourishment, we noted increased abundance of R. gnavus 
and decreased Lachnospiracae and Ruminococcaceae families. The abundance of butyrate-
producing organisms also declined with increasing frailty and malnutrition. Similar dysbiotic 
patterns have been observed in the disease states of IBD [136, 158, 159] [137] as well as in 
systemic inflammatory disorders such as multiple sclerosis [160]. Butyrate is an essential 
metabolite in the human colon. It is the preferred energy source for the colonic epithelial cells 
and it contributes to the gut barrier maintenance as well as having both immunomodulatory and 
anti-inflammatory properties [138]. Our finding adds to the growing evidence that a dysbiotic gut 
microbiota, with reduced butyrate production, is linked to medical disorders and may be a target 
of dietary and probiotic interventions.  
Lipopolysaccharides and PGN biosynthesis was increased in frail or malnourished 
residents. Both of these gut-microbiota derived molecules stimulate specific systemic 
inflammatory pathways that result in low-grade systemic inflammation [143]. LPS- and PGN-
associated inflammation has been linked to central nervous system disorders (e.g. chronic fatigue 
syndrome and complex regional pain syndrome) [161], as well as colorectal carcinoma tumor 
progression [162], and obesity and obesity-related pathologies [163]. Additionally, patients who 
have had a stroke or cardiovascular disease have had a greater inflammatory gut profile with an 
increase in PGN-producing enzymes [164]. Besides LPS and PGN biosynthesis, residents with 
higher frailty scores also were enriched in genes for sphingolipid metabolism. Alterations of 
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sphingolipids metabolisms have been associated with IBD [157] and nonalcoholic fatty liver 
disease [165]. Changes in sphingolipid levels result in a variety of effects on the epithelial barrier 
integrity, immune cell targeting and signaling, and innate/adaptive immune responses [142]. 
Taken together, elderly nursing home residents with higher frailty scores associated with a 
dysbiotic microbiota that resembles an inflammatory gut profile. 
The NH had 2 floors where the residents did not leave that location and 2 floors of higher 
functioning elders that intermingled and used common socialization areas. Importantly, all 
residents were provided the same diet. From the linear-mixed effect modeling, we noted that 
several bacterial species were uniquely associated with specific floors irrespective of age, frailty, 
and malnutrition. The dementia floor had greater abundances of C. catus and E. ventriosum 
whereas both the dementia and medical floor had higher abundances of dysbiotic bacterial 
species. C. bolteae, an organism that causes opportunistic infections [147, 148] as well as R. 
gnavus, which characterizes the dysbiosis seen in IBD patients [148, 159] and also causes 
opportunistic infections [166] were both present in residents living on the 3rd and 4th  floors. Of 
note, residents from these floors had more frequent contact with the hospital setting. The 
healthier residents of the 5th and 6th floor, had both higher abundances of L. bacterium, a 
butyrate-producing organism [140, 141] as well as L. reuteri, a species used as a probiotic for its 
anti-inflammatory effects [150]. When we performed the phylogenetic tree analysis of E. coli, 
resident sequences from the 5th and 6th floors intermingled while the 4th floor residents were 
genetically separate. Taken together, the location of the resident in the NH had associations with 
both specific enriched bacteria organisms and genetically similar E. coli phylogeny. 
 
4.1. Strengths and Limitations 
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This study had several notable strengths and limitations. One limitation of this study is 
that it reports data from only a single site, however this is balanced by the strengths that all study 
participants had the same diet, effectively removing this important covariate. To our knowledge 
all previous elder microbiome investigations did not account for variations in diet. This study is 
also limited in the number of residents enrolled. The limited sample size may affect the 
generalizability of our findings especially when it concerns elders with varying medical 
comorbidities. Other potentially confounding variables such as polypharmacy and specific 
classes of medications the residents were exposed to were not evaluated in this cohort. Finally, 
the physical location microbiome association findings may have been biased by the clustering of 
residents with similar medical conditions onto the same floor. Following up this investigation 
with a multi-center cohort study would strengthen the findings and further explore the dysbiosis 
associations with age and frailty.  However, we report new findings with regards to malnutrition 
and physical location within a the nursing home among elders. Confirming our study’s findings 
in multiple NH facilities and addressing how these dysbiotic patterns are associated with C. 
difficile or MDRO colonization would be key to improving the health and wellbeing of elders 
living in the NH setting.  
4.2. Conclusions 
In conclusion, the dysbiosis of the NH elderly gut microbiome not only differs with 
increasing age, frailty, and nutrition, but also physical location within the NH. Further work is 
needed to see if introducing dietary changes or probiotics could affect these relationships with a 
goal of moving the microbiome away from being dysbiotic and supporting inflammation towards 
a healthier non-inflammatory profile that could help prevent disease.  
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5. TABLES AND FIGURES 
Table 2.1: Characteristics of the Nursing Home Cohort by Floor of Residence 
Floor Number 
(n) 
Third (3) Fourth (4) Fifth (7) Sixth(8) p-value 
      
Age 82 (2.0) 96.4 (4.6) 89.9 (7.1) 86.3 (8.4) 0.036 
Age Category 2 (0.0) 3.6 (0.5) 2.9 (0.9) 2.5 (0.8) 0.010 
Length of Stay 23 (18.2) 14.6 (19.2) 22.9 (32.3) 17.9 (22.2) 0.93 
CCI Score 2 (1.7) 1 (1.7) 1.3 (1.8) 1.0 (1.4) 0.82 
Malnutrition 1 (0.0) 1.6 (0.5) 0.6 (0.5) 0.4 (0.5) 0.008 
Frailty 6.7 (0.6) 6.8 (0.8) 4.9 (0.9) 4.9 (0.6) 0.053 
Data presented as means (sd). CCI = Charlston Comorbidity Index, Length of Stay in months, 
Age Category 1= 65-74, 2 = 75-84, 3 = 85-94, and 4 = ≥95 
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Figure 2.1. Individual variability of the microbiome over time 
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Figure 2.1 Legend: (a) A distance matrix of sample similarity from the presence or absence of 
bacterial species in each sample using the Jaccard Binary Index. Sample-to-sample distances are 
presented in a 2D Principal Component Analysis plot. Samples from 6 nursing home residents 
are colored by participant. No resident experienced any change in medications or a healthcare 
event over the sampling period. Each point represents a sample time point taken at 3 day and 
then 30 day intervals over a 4 month period of time. (b) The different community compositions 
among the six residents defined at the order level. 
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Figure 2.2 Binary jaccard  index principal component analysis 
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Figure 2.2 Legend: (a) Binary Jaccard  Index principal component analysis by age category and 
frailty score. The Jaccard Binary Index compares similarity in presence or absence of bacterial 
species in the microbiome between samples.  Residents are categorized into different age groups 
represented by different symbols where category 1 has residents 65 to 74 years, category 2 is 75 
to 84, category 3 is 85 to 94 and category 4 is  ≥95 years of age. Frailty scores are each colored 
differently. (b) Binary Jaccard  Index principal component analysis by malnutrition and frailty 
score. Malnutrition scores are represented by different symbols where frailty scores are each 
colored differently. (c) Binary Jaccard  Index principal component analysis by malnutrition and 
floor location. Malnutrition scores are represented by different symbols where each floor is 
colored differently. All the panels display ellipses with confidence interval of 75%. Ellipses are 
drawn for each combination of the grouping variables (e.g. Frailty-5 & Malnutrition 0).  Ellipses 
cannot be drawn for group with less than 4 samples and are therefore omitted from the plots.	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Figure 2.3. Heat map of the relative abundance of each gene type in each individual and 
hierarchical clustering depicting (A)species and (B) pathways 
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Figure 2.3 Legend: (a) The heatmap depicts the relative abundances of gene sequences assigned 
to each bacterial genus (y axis) across the 100 samples analyzed (x axis). The heatmap colors 
represent the relative abundances of the microbial genus assignments within each sample. Square 
colors shifted towards red to indicate higher abundance. The colored bars across the top of the 
graph depict the frailty score, age category, malnutrition score, floor location and finally 
individual resident from top to bottom. (b) This heatmap differs by depicting the relative 
abundances of gene sequences assigned to each kegg pathway (y axis) across the 100 samples 
analyzed (x axis). 
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Figure 2.4. Essential amino acids by age 
	  
Figure 4 Legend: Relative abundances of essential amino acid pathways by age category: 1) 65 
to 74; 2) 75 to 84; 3) 85 to 94; and 4) ≥95 years of age. Data presented as boxplots with the box 
being the first and third quartiles, the band inside the box is the median, and the wiskers 
represent the 95th percentiles. Each pathway depicted is as follows: (a), Cystine and methionine 
metabolism; (b), Valine, leucine and isoleucine biosynthesis;  (c), Lysine biosynthesis; and (d), 
Histidine metabolism.  	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Figure 2.5. Butyrate-producing bacteria by frailty 
	  
Figure 5 Legend: Relative abundances of butyrate-producing organisms by Clinical Frailty 
Score. Data presented as boxplots with the box being the first and third quartiles, the band inside 
the box is the median, and the wiskers represent the 95th percentiles. Each organism depicted is 
as follows: (a), Eubacterium eligens; (b), Eubacterium ramulus; (c), Lachnospiraceae bacterium; 
(d), Roseburia hominis; (e), Roseburia unclassified; (f), Ruminococcus obeum 
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Figure 2.6: Bacterial species by floor 
	  
Figure 6 Legend: Relative abundances of organisms by floor in the nursing home. Data presented 
as boxplots with the box being the first and third quartiles, the band inside the box is the median, 
and the wiskers represent the 95th percentiles. The dots represent the outliers. Each organism 
depicted is as follows: (a), Clostridium bolteae; (b), Coprococcus catus; (c), Eubacterium 
ventriosum; (d), Lachnospiraceae bacterium; (e), Ruminococcus gnavus.  
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Figure 2.7. Phylogenetic tree of Escherichia coli by individual resident and floor 
	  
	  
Figure 7 Legend: The phylogenic tree of Escherichia coli species from seven of the individual 
residents for whom sequence data was abundant enough to map. The identification numbers 
listed represent a unique sample time-point. Each individual resident is color coded and their 
floor location noted on the graph. The ambulatory residents on the 5th and 6th floors 
(pink/yellow/green colored) had more similar Escherichia coli phylogeny than patients on the 4th 
floor (blue/purple colored). 
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CHAPTER 3 
Patterns of Clostridium difficile Colonization among Nursing Home Elders and the 
Associations with Clinical Characteristics and Microbiome Composition 
 
ABSTRACT 
Background: Clostridium difficile disproportionally affects the elderly nursing home (NH) 
population, and high prevalence rates of C. difficile colonization may be to blame. Our objective 
was to explore the colonization patterns seen in NH elders, over time, to identify clinical and 
microbiome based factors that are associated with colonization status.  
 
Methodology: We constructed a cohort of NH residents ≥65 years of age that lived in four NH 
facilities in central Massachusetts from whom we collected stool samples for 4 sequential 
months. Key clinical variables were extracted from the medical record. C. difficile colonization 
was determined by real-time polymerase-chain reaction detection of Toxin genes tcdA and tcdB. 
Bacterial composition of resident stool samples was determined by metagenomic sequencing. 
We performed bivariate analysis followed by logistic regression to identify the association 
between clinical variables and colonization status. We used random forest machine learning to 
identify bacterial species that were predictive of colonization. 
 
Results: We enrolled 91 NH elders who contributed 292 clinical samples. Of these, 34 (37.4%) 
of the residents had one time point in which C. difficile was detected and 16 (47.1%) had 
multiple stool samples where C. difficile was detected. Residents with daily acid reducing 
medication use were 76% less likely to be colonized with C. difficile than residents not taking 
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this type of medication (odds ratio [OR] of 0.24; 95% confidence interval [CI], 0.08 to 0.71). 
Microbiome composition was similar among elders living together, and the microbiomes of 
roommates closely approximated each other. Microbiome species with known relationships to C. 
difficile predicted colonization.   
 
Conclusion: C. difficile colonization is common among NH elders and is associated with prior 
antibiotic exposures and inversely related to acid reducing medication use. The microbiome of 
NH elders is influenced by the environment in which they live and key intestinal bacterial 
species are predictive of C. difficile colonization.  
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1. INTRODUCTION 
The elderly are disproportionally affected by the ongoing Clostridium difficile infection 
(CDI) epidemic.[40, 41] The rate of CDI is several folds higher in persons age 65 year and older 
[42] with an increase in risk of 2% for each year starting at 65.[43] The rate of CDI is 
228/100,000 in those 65 and older compared to 40/100,000 in those aged 45-64 years and 
11/100,000 in patients 15-45 years of age. Not only are elders at increased risk of acquiring CDI 
but they also have higher rates of complications, recurrence, and death.[26] Elders living in 
nursing homes are now the predominant group suffering from CDI.[40, 44] On average, 40 to 
50% of new CDI cases come from elders living in nursing homes.[45, 46] Most NHs in the US 
have a structured infection prevention and control programs, [167] however environmental 
measures to control CDI, such as enforcing hand hygiene, contact precautions, and 
decontamination procedures only after CDI is identified have not been able to stem this CDI 
concern. [16] 
One factor that has become of increasing contemporary interest and a target of preventive 
strategies is the human microbiome. The microbiome is a vast ecosystem of microbes that 
influence human health and disease.[52] The intestinal flora changes with age, especially as the 
presence of anaerobes decreases.[53, 54] Elders from nursing homes differ from community-
dwelling counterparts in their microbiome composition with higher proportions of the phylum 
Bacteroidetes and lower proportions of other bacteria at the family and genus levels.[55] The 
microbiome of nursing home elders forms dysbiotic patterns with increasing age, frailty and 
malnutrition.[168] Microbial dysbiosis can be in the form of abnormal function or an association 
with disease. Connecting these dysbiotic patterns and attempting to correct them may serve as a 
means to prevent CDI.   
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Another target for CDI prevention is reducing the amount of C. difficile present in the 
environment. The rates of C. difficile present in the stool are the highest in nursing homes, with 
20% to 50% of residents affected compared to 1.6% in the general community and 9.5% in the 
outpatient setting.[53, 58] Carriage of C. difficile is a well-documented source of new CDI cases 
from spread of the bacteria, however approaches to managing carriage as a means to prevent CDI 
are lacking.[59-61] The risks of C. difficile colonization in nursing home elders have been 
understudied to date.  
A better understanding of C. difficile colonization in the nursing home and how it is 
associated with clinical factors and microbiome composition would provide a novel tool into 
combating the CDI epidemic. Accordingly, we set out to follow longitudinally a cohort of elders 
from multiple NH facilities to investigate: 1) the patterns and rates of C. difficile colonization; 2) 
the associations of C. difficile colonization to medication exposures and other clinical variables; 
and 3) the microbiome’s association with C. difficile colonization status. Our findings contribute 
to the understanding of how the microbiome composition associates with C. difficile colonization 
as a potential target to reduce CDI burden in the elderly. 
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2. METHODS 
2.1. Study Setting and Population 
This prospective cohort study was approved by the institutional review board at the 
University of Massachusetts Medical School. This cohort is of NH residents ≥65 years of age 
who lived in one of four NH facilities in central Massachusetts. We approached residents who 
had been living in the facility for ≥1 month and did not have any diarrheal illness or 
antimicrobial exposure within the preceding 4 weeks. Our trained staff used a standardized 
Capacity for Informed Consent Instrument [169] that combines capacity assessment questions 
with observation. If the resident was deemed unable to provide consent, we contacted the 
healthcare proxy to obtain informed consent. Residents were enrolled for a minimum of 4 
months. No patients suffered from dysphagia or had a feeding tube.  
2.2. Data Collection  
We conducted baseline and end of study medical record abstraction for factors associated 
with key study variables. Here our outcome was C. difficile colonization and our variables of 
interest included age, frailty, malnutrition, location and medication exposures. We used the 
medical records as the “gold standard” of information for resident’s clinical information. 
Variables known to be associated with C. difficile infection were collected and included: 
previous hospital exposure, chronic dialysis, steroid or immunosuppressant medication, 
antibiotic use, and gastric acid suppressant use.[170, 171] Resident Characteristics included age 
and sex. Other factors we have previously reported on being associated with intestinal microbial 
dysbiosis included: nutritional status, comorbidities, medications, and frailty [55]. Prior history 
of hospitalizations, antibiotic exposures in the past year, and history of C. difficile infections 
were extracted from the medical record as well as basic demographic data including age, sex, 
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race, and length of NH stay. We categorized residents into 4 age categories for analysis: 1) 65 to 
74; 2) 75 to 84; 3) 85 to 94; and 4) ≥95 years of age. Frailty was measured in two ways: (1) the 
validated and widely utilized Canadian Study of Health and Aging’s (CSHA) 7-point Clinical 
Frailty Scale (CFS) [119]; and (2) the Edmonton Frailty Scale (EFS).[172] The CFS is a 
categorical scaling system containing 9 categories ranging from very fit to terminally ill. Since 
we were enrolling elders in the nursing home not on hospice, our scale ranged from 3 (managing 
well) to 8 (very severely frail). The EFS is a continuous scoring system combining general health 
questions, nutrition, functional performance, and cognition. These scoring systems have been 
previously validated for demonstrating signatures of frailty in the gut microbiota [120, 121]. We 
assessed nutritional status using the Mini Nutritional Assessment (MNA) tool [122-124]. 
Residents were categorized as normal, at risk, or malnourished based on the MNA survey 
administered by trained research staff to the residents or the nurse caring for the resident if 
mentally impaired. All residents enrolled were monitored during their involvement in the study 
for any changes to their care or for new exposures.  
2.3. Sample Collection and Processing 
We collected 4 monthly stool samples from each resident. DNA was extracted from 
samples using the PowerMagTM Soil DNA Isolation Kit on an epMotion 5075 TMX liquid 
handling workstation according to manufacture protocols (MO BIO Laboratories, #27100-4-EP). 
Sequencing libraries were constructed using the Nextera XT DNA Library Prep Kit (Illumina, 
Inc., #FC-131-1096) and sequenced on a NextSeq 500 Sequencing System as 2 x 150 base pair-
end reads. 
2.4. Detection C. difficile colonization as outcome  
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All samples were tested for C. difficile toxin genes to determine C. difficile colonization. 
This was done using real-time polymerase-chain reaction with AdvanSure RT-PCR kit (LG Life 
Science) for the simultaneous detection of tcdA and tcdB genes. The primers target sequences of 
the tcdA and tcdB genes based on TaqMan technology. We used the SLAN RTPCR detection 
system (LG Life Science) according to the manufacturer’s instructions.[173] Each sample 
needed to be positive for both tcdA and tcdB genes to then be categorized as positive for C. 
difficile. We categorized residents into two outcome categories. The first being residents that had 
any stool sample positive for C. difficile and the second, residents that had multiple time points 
in which they had stool samples positive for colonization (multi-colonization).  
2.5. Sequence Processing and Analysis 
Shotgun metagenomic reads were first trimmed and filtered to remove sequencing 
adapters and host contamination using Trimmomatic [125] and Bowtie2 [126], respectively, as 
part of the KneadData pipeline (https://bitbucket.org/biobakery/kneaddata). Reads were then 
profiled for microbial species abundances using Metaphlan2 [127] and for abundance of Uniref 
genes, KEGG orthologues, and of the corresponding functional pathways (Metacyc pathways, 
KEGG pathways, and KEGG modules) using the software pipeline HUMAnN2 [128] and in-
house written scripts (available upon request). Normalized taxonomic, gene, and pathway 
abundances were then used for downstream statistical analysis in R (see below). Strain-level 
analysis of Escherichia coli present in metagenomic samples was performed using StrainPhlAn 
[129]. Reads were mapped against the MetaPhlan2 clade-specific marker gene database [130].  
Reconstructed E.coli-specific consensus markers were derived from the mapping data. The 
reconstructed markers were then used to build a phylogeny of the strains. The tools cited, in turn, 
depend upon the following tools—for KneadData: Trimmomatic [125], Bowtie2 [131], 
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SAMtools (https://github.com/samtools/); for StrainPhlan: MetaPhlan2 [130], MUSCLE [132], 
RAxML [133], blastn [134]. The phylogenetic tree was visualized with FigTree 
(http://tree.bio.ed.ac.uk/software/figtree/) 
2.6. Data Analysis 
We performed traditional unsupervised correspondence analysis (NMDS and 
unsupervised hierarchical clustering) to first determine samples similarity with respect to the 
above covariates of age, frailty, malnutrition, acid medication use, and physical location. 
Permutation Multivariate Analysis of Variance (PERMANOVA) was performed to evaluate 
inter- vs intra-individual variability in bacterial abundance. To determine the contribution of 
each covariate to changes in microbiome composition (including microbial and functional 
pathways abundances) we performed linear-mixed effect modeling regression after arcsine 
square root transformation [81] using the R package lme4. P-values were calculated using a 
Kenward-Roger Degrees of Freedom Approximation and the returned t-value from the 
regression modeling. Covariates with  p < 0.05 were retained and used for downstream 
visualization and data interpretation.  
We used multivariable logistic regression analysis to test whether clinical variables alone 
were associated with C. difficile colonization. To select the set of covariates for the multivariable 
model, we selected any covariates with a p<0.20 from our unadjusted bivariate analysis. We ran 
two models, first with the outcome of any colonization time point and then again with the 
outcome of multiple colonization time points. We included all acid reducing medications rather 
than proton pump inhibitors alone in the model given both were significantly associated with the 
outcome.  
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Finally we used random forests technique to examine a large ensemble of decision trees 
of bacterial species composition of the microbiome in predicting C. difficile colonization status. 
Variable importance plot was used with mean decrease accuracy to identify species important in 
predicting colonization and explored these species relationship (greater or lesser abundances) to 
colonization.  
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3. RESULTS 
3.1. Characteristics of the Study Subjects  
Over a seventeen-month period we enrolled and followed 91 NH elders from 4 different 
facilities collecting monthly samples, totaling 292 clinical samples. We obtained a complete 
stool sample collection from all time points among 44 (48.4%) of the residents enrolled. We 
were unable to obtain complete samples from the remaining residents due to a variety of reasons 
which are outlined in Figure 3.1. Reasons for incomplete sample collection included issues with 
the facility staff on a given floor, the resident choosing to withdraw from the study, resident 
death, nursing withdrawal of the resident, or if the resident moved out of the NH. Of note several 
facilities had delayed enrollment and were not able to get complete sample collection by the time 
of this study’s completion. No residents included in this analysis were exposed to antimicrobials 
or were hospitalized during the study period. The last antimicrobial exposure occurred three 
months’ prior to enrollment in only one subject. Of the residents enrolled, the average age was 
84.4 years (SD 9.5), 19.8% were male, with 25 (27.5%) having been hospitalized and 29 (32.6%) 
having an antimicrobial exposure in the preceding year.  
3.2. Clostridium difficile colonization and clinical associations  
 Of the 296 samples collected 56 (18.9%) were positive for C. difficile. Over the course of 
the study 34 (37.4%) residents had one time point in which C. difficile was detected in the stool. 
Out of these 18 (53.9%) had only one sample positive for C. difficile while 16 (47.1%) had 
multiple time points in which C. difficile was detected. The number and percentage of residents 
colonized by C. difficile varied by both the nursing home facility and floor/wing in which the 
elder lived (Figure 3.2). This ranged from 28.0% to 50.0% across the four sites and went as low 
as 12.5% on one floor to as high as 57.1% on another. Residents exposed to acid reducing 
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medications were 76% less likely to be colonized with C. difficile than residents not taking this 
type of medication (Odds Ratio [OR] of 0.24; 95% confidence interval [CI], 0.08 to 0.71). We 
did not see any differences in resident demographics or clinical scores (for both frailty and 
malnutrition) among colonized and non-colonized residents (Table 3.1). Of note, residents 
colonized with C. difficile had a non-statistically significant higher percentage of an antibiotic 
exposure within the preceding 6 months. The association of acid reducing medication use and 
colonization did not differ when looking at the second outcome of multi-colonization. 
 In our multivariable logistic regression, which included clinical covariates with a p<0.20, 
residents taking acid reducing medications had 83% reduced risk of C. difficile colonization 
compared to those not taking this class of medication (Table 3.2). Additionally, residents 
exposed to antibiotics in the preceding 6 months had over 3 times the risk of C. difficile 
colonization than those not exposed (OR 3.42; 95%CI 1.01 – 11.91). Only the significance of 
acid reducing medication use remained the same when the model was re-run with multi-
colonization as the outcome.  
3.3. Microbiome similarity among residents within the same facility 
 We explored beta-diversity by principal coordinate analysis (PCA) using Bray–Curtis 
Index principal component analysis. The Bray–Curtis dissimilarity is a compositional 
(abundance) dissimilarity that is bounded between 0 and 1, where 0 means the two sites have the 
same composition (that is they share all the species), and 1 means the two sites do not share any 
species. Bray–Curtis distances for a measure of community species dissimilarity among residents 
is broken down by nursing home site in Figure 3.3. We note a pattern of shifting of microbiome 
composition from each resident towards residents from the same facility. This is not a clear 
separation but residents from facilities seem to group together with some overlap. For example, 
	   59	  
residents from site 4 (purple) cluster towards the middle with site 3 (green) and 2 (orange) 
around them as you move towards the periphery. Residents from site one (blue) seem to make up 
the majority of the periphery in 3D space. When we look to elders who were roommates we 
notice that residents that share the same room during the study period (larger color coded circles) 
tend to approximate each other (Figure 3.4). Microbiota compositional differences were greater 
between the covariates of both site and floor than within them with a PERMANOVA – Jaccard 
distance p=0.05 for site and p=0.001 for floor.  
We explored whether residents share genetically similar strains of bacteria. Sharing 
strains between NH residents housed together in the same facility or on the same floor could 
have implications with respect to transmission of infections. We constructed the phylogenic tree 
of Escherichia coli species from 29 samples that mapped from18 individual residents from all 4 
facilities using metagenomic sequence data, Figure 3.5. Escherichia coli was chosen for strain-
level analysis due to it being both a common bacterial species that colonizes the intestines and is 
a species known to cause disease (i.e., urinary tract infections). The phylogenic tree demonstrates 
that residents at the same facility had E. coli strains sharing more similar phylogenetic 
relationships than residents living at other facilities. Additionally five of the residents with 
multiple samples mapping had E. coli phylogeny that did not change over time, suggesting they 
maintained that same strain over time. These data suggest that residents that live together in both 
the same facility and even on the same floor within that facility had genetically related E. coli 
strains compared to other residents living in a separate floors/facilities that did not intermingle. 
3.4. Clostridium difficile colonization and the intestinal microbiome 
 By exploring beta-diversity by principal coordinate analysis (PCA) using Bray–Curtis 
Index, we were able to investigate if residents that are colonized at any time point or who are 
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colonized at multiple time points have similar microbiome diversity profiles (Figure 3.6a. and 
3.6b.). Microbiota compositional differences were greater between the outcomes of C. difficile 
colonization and multi-C. difficile colonization than within them with a PERMANOVA – 
Jaccard distance p=0.002 and p=0.001 for each. First, with regards C. difficile colonization, we 
note a pattern of shifting of composition towards the bottom/base of the plot as the resident is 
categorized as a colonized resident, Figure 3.6a. Furthermore we see clearer delineation when 
looking at the outcome of multi-colonization, Figure 3.6b. In comparison we plotted the beta-
diversity for residents on acid reducing medications and noted an inverse relationship (Figure 
3.7.). 
 In order to select bacterial species that are predictive of the outcome of C. difficile 
colonization, we used random forests.  Random forests technique is a machine leaning 
methodology for classification of variables by constructing multiple decision trees that predict in 
this case the outcome of colonization. The variable importance plot orders from greatest to least 
the bacterial species most predictive of colonization (Figure 3.8.). Among the most predictive 
are several species of the Bacteroides genus (Figure 3.9.) that have been previously reported in 
the literature as being associated with C. difficile colonization. Ruminococcus gnavus, a bacterial 
species that has been reported as being associated with dysbiotic microbiomes, and CDI was 
seen in higher abundances in C. difficile colonized residents. In addition to the members of the 
Bacteroides genus, Akkermasnsia muciniphila was present in lower abundances and 
Bacteroidales bacterium ph8 was present in higher abundances in colonized samples. These 
species have been reported to have an inverse relationship to CDI in the literature (A. 
muciniphila higher in CDI and B. bacterium lower in CDI) (Figure 3.10b-c). Finally, there are 
several species identified as important in predicting C. difficile colonization that were at lower 
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abundances in colonized samples that have been reported to exhibit an inhibitory effect against 
C. difficile (Figure 3.10d-e).  
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4. DISCUSSION 
Nursing home residents demonstrated high C. difficile prevalence in our study with 
colonized residents having clinical associations with recent antibiotic exposure and an inverse 
relation to acid reducing medication use (i.e. more non-colonized residents were daily acid 
reducing medication users). The nursing home environment had significant influences on 
intestinal microbiome composition with residents in the same facility having similar diversity 
patterns, roommates approximating the others’ microbiome profile, and sharing of E. coli strains 
among residents at the same NH facilities. Finally, there is an intestinal microbiome 
composition, with key known species that have reported associations to CDI and colonization in 
the literature, which we identified as predicting C. difficile colonization. This gives a preliminary 
signature of susceptibility to being colonized with C. difficile in nursing home elders. 
4.1. Clostridium difficile colonization is common among NH elders 
 Over one-third of residents enrolled in our study were colonized with C. difficile at least 
one point over the 4 months in which we collected samples with roughly half of the colonized 
residents having multiple samples positive for C. difficile. These residents with multiple positive 
samples represent a group of long-term colonized elders that could serve as reservoirs of C. 
difficile rather than those with only one sample positive, or transiently colonized elders.  This 
ranged as low as 28% at one site to as high as 50% at another. Our findings are consistent with 
other C. difficile colonization studies in nursing homes that demonstrated a range of colonization 
from 20% to 50% of residents sampled.[53, 58] 
4.2. Acid reducing medication are associated with a reduced risk of Clostridium difficile 
colonization 
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Acid-reducing medications, including both PPIs and H2 blockers classes of medications, 
have been known for quite some time to be associated with an increased risk of CDI.[107] A 
recent large systematic review and meta-analysis including 56 studies involving 366,683 patients 
demonstrated a pooled Odds Ratio of 1.99, CI: 1.73-2.30, P < 0.001.[174] This meta-analysis 
provided further evidence that PPI use is associated with an increased risk for development of 
CDI. However, whether this is causation or association is still up for debate given that the 
mechanism by which acid reducing therapy contributes to an increased risk of CDI is still 
unknown.[29, 108]  
 Many mechanisms by which acid reducing therapy causes CDI have been proposed. This 
started with the theory that the vegetative form of C. difficile has a better chance of survival 
when gastric conditions have a pH greater than 4. [175] This theory has recently been refuted by 
investigations in both mouse models and hospitalized patients where C. difficile spores were not 
affected by the acid gastric pH content. [176] Other mechanisms have been proposed. PPI 
therapy has been shown to affect the human colonic epithelium by decreasing the expression of 
human genes holding an important role in mucosal integrity, thus favoring the development of 
CDI. [177] With increasing attention to the intestinal microbiome and its relationship to CDI, 
long-term use of PPIs has been shown to decrease microbial diversity, a similar condition found 
in patients with CDI. [178] Besides diversity, differences among bacterial species composition in 
the intestines between PPI users and non-users are consistently associated with changes towards 
a less healthy gut microbiome and are in line with known changes in the microbiome that 
predispose individuals to CDI.[109, 179]  
 In our study, we found that residents taking acid reducing medications had a reduced risk 
of C. difficile colonization. There are few studies of C. difficile colonization in the elderly, 
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especially ones involving elders living in nursing homes. The systematic review noted above did 
not reveal any association with PPI and C. difficile in the elderly. [174] Among older 
hospitalized adults, treatment upon admission with PPIs has not been shown to be associated 
with C. difficile colonization. [180] The use of PPI was also shown not to be associated with C. 
difficile colonization in previous studies with a lower number of subjects, 68 long-term care 
elders, although a non-statistically significant higher percentage of colonized residents were on a 
PPI.[58] Our findings suggest that changes in the intestinal microbiome with acid reducing 
medication use may be associated with a less favorable environment for C. difficile colonization.  
4.3. Importance of environment in shaping the intestinal microbiota 
 We are reporting here how the microbiome composition is more similar among residents 
living at the same facility compared to those at other facilities and how the microbiomes of 
roommates’ microbiomes are similar to each other. We also demonstrated that resident’s living 
together share similar E. coli strains by phylogenic tree analysis. Taken together, the location of 
the resident in the NH was associated with microbiome composition and bacterial phylogeny 
suggesting that there is sharing of bacteria among residents living together. The influence of 
environment in shaping the intestinal microbiome in the literature is becoming more apparent. 
One recent study of over 1,000 healthy individuals demonstrated that there are significant 
similarities in the compositions of the microbiomes of genetically unrelated individuals who 
share a household.[181] They go on to state that only about 20% of the inter-person microbiome 
variability is associated with factors related to diet and medications. Our findings echo these and 
highlight the importance of grouping vulnerable elders together. It also places an importance on 
environmental control as a means to control microbiome composition, preventing pathogen 
spread, and potentially preventing healthcare associated diseases. We are only starting to 
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understand how the NH environment influences microbiome composition. A key next step would 
be to manipulate the environment to influence microbiome composition towards one less likely 
to promote colonization. The exact methods to do this still need to be determined.  
4.4. Microbiome composition and Clostridium difficile colonization 
One of the more frequently cited combinations of microbial bacterial community 
compositions associated with CDI involve higher abundances of Peptostreptococcaceae and 
Enterococcus, with decreased population density of Bacteroides.[182] In this study we found 
that increases in Bacteroides species were associated with C. difficile colonization. This 
interesting inverted relationship of higher abundances of bacterial species associating with C. 
difficile colonization but lower abundances associating with infection, especially in the care of 
the Bacteroides species, has been known for some time.[183, 184] Bacteroides are abundant 
commensal members of the human intestinal microbiome. They are involved in key metabolic 
processes, including carbohydrate fermentation and polysaccharide production, and their ability 
to modulate surface polysaccharides helps them to evade host immune systems.[185] The 
mechanisms by which they promote colonization but resist infection are not known.  
We also found other species associated with colonization here whose relationship to 
colonization had previously been reported. The presence of Firmicutes species, such 
as Ruminococcus gnavus, in significant quantities is associated with C. difficile  
colonization.[186] This species, however, has been shown to produce a trypsin-dependent 
antimicrobial substance against C. difficile.[187] Ruminococcus gnavus is also known for its 
association with a dysbiotic microbiota.[136] We found higher abundances of several of the 
Ruminococcus species in our C. difficile colonized residents.  
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We also found other bacterial species that are positively associated with CDI in the 
literature but inversely related to colonization here. For example, we noted that there were lower 
abundances of Akkermansia muciniphila in the C. difficile colonized residents where increased 
abundances of this species has been noted in CDI patients. [182] Akkermansia over-
representation may reflect enteric mucosa inflammation in CDI with increased mucus 
production.[121] Another species positively associated with C. difficile colonization in our study 
but also seen in lower abundances in CDI was Bacteroidales. [182] Bacteroidales are known to 
produce butyrate, a short chain fatty acid that has been shown to promote colonic barrier strength 
at appropriate concentrations by increasing mucin production, decreasing colonic permeability, 
and thereby reducing the susceptibility of the colon to infections.[188] Finally species that have 
known inhibitory effects on C. difficile such as Bacteroides ovatus, [189] and Lachnospiraceae 
bacterium, [190] were in lower abundances.  
Taken together the species identified here as important in predicting C. 
difficile colonization are known to associate with either a colonized or infected state and some 
key combination of these groups probably provide a suitable environment for C. difficile to take 
hold and grow without causing disease symptoms (i.e. toxin producing diarrhea). Interestingly, 
similar to our findings where acid reducing medication use reduced the risk of colonization but is 
reported in the literature to increase the risk of infection, the associations of specific bacterial 
species, in either increased or decreased abundances, reported in the literature with CDI we 
noticed an inverse association with C. difficile colonization (i.e. higher abundances in infection 
lower in colonization).   
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4.5. Strengths and Limitations 
This study had several notable strengths and limitations. One limitation of this study is 
that it did not have 4 stool samples from each resident. This may have led to misclassification of 
the secondary outcome of multi-colonization in these residents. This is the largest longitudinal 
cohort of nursing home elders reporting microbiome composition. It is also the largest study to 
survey NH residents for C. difficile colonization. That being said this study is still limited in the 
number of residents enrolled. A more robust cohort would help us to take a much deeper look at 
the multiple levels of data and to better explore other classes of medications used less frequently 
by NH elders. There are potential confounding variables, specifically classes of medications the 
residents were taking (such as corticosteroids and immunosuppressants) that were not evaluated 
in this cohort due to the small number of residents on these drugs. Finally, the physical location 
microbiome association findings may have been biased by the clustering of residents with similar 
medical conditions onto the same floor. Following up this investigation with a cohort including 
larger numbers of residents from more facilities would strengthen the findings and further 
explore the dysbiosis associations with medication exposure in the elderly and further address 
how these dysbiotic patterns are associated with C. difficile colonization.  
4.6. Conclusions 
In conclusion, C. difficile colonization is common among NH elders with a large portion 
of these colonized residents harboring this pathogen over the course of months. We found that 
the NH elderly intestinal microbiome is influenced by the environment in which the elder lives 
but this did not seem to influence the C. difficile colonization state. C. difficile colonization state 
was associated with prior antibiotic exposures and inversely related to acid reducing medication 
use. Finally we found that the abundances of several key intestinal bacterial species were 
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associated with C. difficile colonization. Further work is needed to see if a microbiome based 
model could predict C. difficile colonization and then if the use of  interventions to change the 
elder microbiome to one that favors colonization resistance could affect high rates of C. difficile 
colonization seen within the nursing home, thus preventing this disease.  
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5. TABLES AND FIGURES 
 
Figure 3.1. Sample collection flow diagram 
 
 
 
Figure Legend: This flow diagram outlines the reasons for incomplete sample collection. This 
included: Floor - issues with the facility staff on a given unit; Resident -  resident’s choosing to 
withdraw from the study; Death - resident death during study activities; Nurse - nursing 
withdrawal of the resident due to collection issues; and Moved - resident moved out of the 
facility. Of note several facilities had delayed enrollment and were not able to get complete 
sample collection by the time of this study’s completion (Ongoing). 
 
Figure 3.2. Breakdown of resident enrollment and colonization outcome by nursing home 
site 
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Figure 3.3. Bray-Curtis index principal component analysis of residents by facility site 
 
 
 
 
Figure 3.3 Legend: Bray–Curtis Index principal component analysis by facility location. The 
Bray–Curtis dissimilarity is bounded between 0 and 1, where 0 means the two sites have the 
same composition (that is they share all the species), and 1 means the two sites do not share any 
species. Each colored dot represents one of the four nursing home sites 
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Figure 3.4. Bray-Curtis index principal component analysis of residents linking roommates 
 
 
 
 
Figure 3.4 Legend: Bray–Curtis Index principal component analysis linking residents that were 
roommates during the study period. The Bray–Curtis dissimilarity is bounded between 0 and 1, 
where 0 means the two sites have the same composition (that is they share all the species), and 1 
means the two sites do not share any species. Each dark blue dot represents a resident that did 
not have a roommate that was involved in the study. Each of the colored dots link the seven 
resident pairs that were giving stool samples during the same time period.  
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Figure 3.5. The phylogenic tree of Escherichia coli species from residents by facility  
 
 
Figure 3.5 Legend: The phylogenic tree of Escherichia coli species from eighteen of the 
individual residents for whom sequence data was abundant enough to map. Each point is a 
unique sample time-point with identification numbers for each resident. Each sample is color 
coded for nursing home facility 1-4 (blue/purple/green/orange colored). 
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Figure 3.6. Bray-Curtis index principal component analysis of residents by Clostridium 
difficile colonization (a) and multi-colonization (b) outcomes 
 
 
 
 
Figure 3.6 Legend: Bray–Curtis Index principal component analysis by Clostridium difficile 
colonization status. The Bray–Curtis dissimilarity is bounded between 0 and 1, where 0 means 
the two sites have the same composition (that is they share all the species), and 1 means the two 
sites do not share any species. The orange dots and the residents positive for Clostridium difficile 
colonization and the blue are controls. (a) Depicts the outcome on any sample being positive for 
Clostridium difficile while (b) depicts the outcome of multi-colonization.  
 
 
a	  
b	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Figure 3.7. Bray-Curtis index principal component analysis by acid reducing medication 
status 
 
Figure 3.6 Legend: Bray–Curtis Index principal component analysis by acid reducing medication 
status. The Bray–Curtis dissimilarity is bounded between 0 and 1, where 0 means the two sites 
have the same composition (that is they share all the species), and 1 means the two sites do not 
share any species. Each dark blue dot represents a resident that was not taking either a proton 
pump inhibitor or an H2 blocker during the study period while the orange dots represent those 
that were.   
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Figure 3.8. Random forests plot of mean decrease accuracy in predicting Clostridium 
difficile colonization 
 
 
 
Figure 3.8 Legend: The variable importance plot of mean decrease accuracy ordering bacterial 
species most important in predicting colonization ordered from most top-to-bottom. The most 
important variables are at the top of the y-axis and an estimate of their importance is given by the 
position of the dot on the x-axis. 
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Figure 3.9. Plots of members of the Bacteriodes genus that appear towards the top of the 
random forests plot 
 
 
Figure 3.9 Legend: Members of the Bacteriodes genus whose increased abundacnes have been 
associated with Clostridium difficile colonization. Species listed starting with (a) the most 
important in predicting colonization by random forest to the least (f).  
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Figure 3.10. Plots of species identifies by the random forests plot as being predictive of 
Clostridium difficile colonization by either being in higher or lower abundances 
 
 
Figure 3.10 Legend: Bacterial species identified by random forests as being predictive of  
Clostridium difficile colonization by either their increased abundances (a,c) or their decreased 
abundances (b,d,e).  
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Table 3.1: Baseline clinical characteristics among residents that were colonized with 
Clostridium difficile at any time point and colonized at multiple time points compared 
to those residents that were not colonized 
 Not Colonized 
(n=57) 
Colonized 
(n=34) 
Multi-Colonized 
(n=16) 
Demographics 
Age (SD) 84.2 (9.5) 84.7 (9.7) 83.2 (10.5) 
Age Category (SD) 2.5 (0.8) 2.6 (0.9) 2.5 (0.8) 
Male  14 (24.6) 4 (11.8) 3 (18.8) 
CCI (SD) 1.7 (1.6) 1.5 (1.7) 0.7 (0.8) 
CCI >=2 30 (52.6) 13 (38.2) 3 (18.8) 
Length of Stay (months) 22.9 (23.2) 27.6 (22.8) 18.1 (17.3) 
Hospital 1yr 19 (33.3) 6 (17.6) 5 (31.3) 
Antibiotics 1yr 16 (28.6) 12 (35.3) 5 (31.3) 
Antibiotics 6mo 8 (14.0) 9 (26.5) 5 (31.3) 
Clinical Scores 
Frailty CFS (SD) 6.3 (1.0) 6.0 (1.0) 5.9 (1.2) 
Frailty Edmond (SD) 7.5 (3.2) 6.7 (3.4) 6.7 (3.9) 
Malnutrition Score (SD) 19.7 (5.7) 20.8 (4.3) 20.8 (4.7) 
Malnutrition Cat. (SD) 2.0 (0.8) 1.9 (0.7) 1.8 (0.7) 
Medication Exposures 
Acid Reducing 24 (42.1) 5 (14.7)* 1 (6.3)* 
PPI 18 (31.6) 4 (11.8)* 0 (0.0)* 
Steroid 4 (7.0) 2 (5.9) 1 (6.3) 
Immunosup 3 (5.3) 1 (2.9) 0 (0.0) 
Data expressed as number (percentage) unless otherwise notes as mean (SD); SD, standard 
deviation; CCI, Charlson comorbidity index; yr, year; mo; months; CFS, Clinical Frailty 
Score; Cat, category; PPI, proton pump inhibitor; Immunosup, immunosuppressant 
medication; Polypharm, polypharamcy (5 or more daily medications) 
*Denotes p value <0.05 
 
 
Table 3.2: Factors significantly affecting the risk of Clostridium difficile colonization from 
multivariable logistic regression 
 Colonization Multi-Colonization 
 Odds Ratio 95% Confidence 
Intervals 
Odds Ratio 95% Confidence 
Intervals 
Frailty Edmond 0.79 0.48 – 1.28 0.51 0.24 – 1.01 
Acid 0.17* 0.05 – 0.60 0.05* 0.01 – 0.56 
Antibiotics 6mo 3.42* 1.01 – 11.91 2.59 0.63 – 10.71 
Hospital 1yr 0.44 0.13 – 1.53 2.17 0.54 – 8.66 
Acid, acid reducing medication use; yr, year; mo; months; 
*Denotes p value <0.05 
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Conclusions 
 No group suffers more from C. difficile than the elderly, especially those living in nursing 
homes. Nursing homes represent the perfect storm of a vulnerable group of frail elders living in 
confined communities. This study has combined different data sources to demonstrate that C. 
difficile colonization and infection is high in the nursing home and that medication exposures are 
associated differently with C. difficile colonization and infection. One reason we believe this 
occurs is the contributions that the intestinal microbiome makes to either resist colonization or 
promote it. Microbiome composition is influenced by many factors in the elderly, such as age, 
frailty, and nutrition. One previously underappreciate factor, which we highlighted for its 
importance in shaping the bacteria that reside in the microbiome, is the living environment.  
 
The first chapter findings highlight differences in the associated risks of rCDI, with 
antibiotic and acid-reducing medication use, after initial CDI treatment that vary depending on 
the home environment. One interesting finding was our discovery that corticosteroid exposure 
was associated with a reduction in the risk of rCDI in community-dwelling elders however is 
associated with an increased risk in nursing home elders. This finding mirrors the reported role 
of corticosteroids where it has been shown to both increase and decrease the risk of incidence of 
and mortality from CDI. [36-39] Corticosteroids have been shown to significantly alter the 
microbiome of the intestine. [111] This might lead to predisposing a patient to rCDI in the form 
of reinfection with a different strain rather than recurrence of the same strain. Our findings of the 
associated increased risk of rCDI with corticosteroid exposure in NH residents does need further 
exploration, however from a clinical standpoint, avoiding corticosteroid use in NH elders after 
CDI treatment could possibly reduce the risk of rCDI. With regards to acid reducing medications 
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and antibiotics, in the nursing home, the risk of rCDI was increased with exposure to acid-
reducing medication but not antibiotics. In the community, antibiotic exposure within the first 6 
months after treatment for CDI was associated with an increased risk of rCDI along with acid-
reducing medication exposure. Our findings add to the literature by highlighting the possible 
importance of the patient’s home environment when it comes to medication exposure and 
associated risks of rCDI. 
 
In the second chapter we demonstrated different dysbiotic associations with increasing 
age, frailty, and malnutrition scores. As the age of residents increased, the abundance of 
microbiota-encoded genes and pathways related to essential amino acid, nitrogenous base, and 
vitamin B production declined. With increasing frailty, residents had lower abundances of 
butyrate-producing organisms, higher abundances of known dysbiotic species, higher LPS and 
PGN biosynthesis, and higher sphingolipid metabolism. Among residents who were at risk of or 
were malnourished, butyrate producing organisms declined and opportunistic and dysbiotic 
bacterial species increased along with PGN biosynthesis. Interestingly, when looking at physical 
location within the nursing home, residents living together shared similar microbiomes and had 
similar E. coli phylogeny shared between them. This highlights the different dysbiotic patterns 
that emerge when looking at key elder factors that influence elder health in the form of 
advancing age, frailty, and malnutrition. We concluded that the dysbiosis of the NH elderly gut 
microbiome not only differs with increasing age, frailty, and nutrition, but also physical location 
within the NH. Physical location might play a vital role in shaping the intestinal microbiome 
which has implications for housing frail elders together and reducing pathogenic bacterial 
spread.  
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In the third and final chapter, we go on to demonstrate that C. difficile colonization is 
common among NH elders from different facilities, is associated with prior antibiotic exposures, 
and inversely related to acid reducing medication use. We demonstrated that the microbiome of 
NH elders is influenced by the environment in which they live which mirrors recent reports in 
the literature where upwards of about 20% of the inter-person variability of the microbiome may 
be attributable to living environment. [181]  Finally, we identified key intestinal bacterial species 
that are predictive of C. difficile colonization. The species identified here as important in 
predicting C. difficile colonization have been previously reported on as being well known to be 
associated with either a C. difficile colonized or infected state. We believe that some key 
combination of these groups probably provide a suitable environment for C. difficile to take hold 
and grow without causing symptomatic disease. Future work in this area would be to better 
define and then validate a microbiome mixture, either supportive or resistant to C. 
difficile colonization, which can then predict colonization risk. This would then inform a rational 
study design to intervene to change the microbiome from a dysbiotic one supporting colonization 
to one that can resist colonization. 
 
This investigation also leaves many unanswered and intriguing questions. Why did 
corticosteroids lead to an increase in recurrence among only NH elders? Why are acid reducing 
medications associated with decreased risk of colonization? Why are bacterial species known to 
be associated with CDI in the literature shown here to have an inverse relationship to C. difficile 
colonization? Our belief is that the microbiome composition plays an integral role in balancing: 
1) if C. difficile can even get established to colonize the gut; and 2) if C. difficile that has 
colonized the gut then starts to overgrow, produce toxin, and lead to symptoms. The medications 
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mentioned above probably play a role in disrupting the microbiome which has different effects 
with regards to colonization and infection (and differ if the elder lives in a NH or in the 
community). The best way to further investigate these associations and prove causation lies in 
first using in vivo or in vitro models to define mechanisms and second expanding this NH cohort 
with larger numbers and longer observation times to capture elders in the NH that then have 
incidental exposures to these medications and others that go on to develop either C. difficile 
colonization or infection. 
 
As we continue to form a better understanding of the intestinal dysbiosis that occurs 
among nursing home elders and how this dysbiosis can be linked to C. difficile disease, we will 
be able to generate insights into novel infection prevention strategies using the aging microbiome 
to prevent C. difficile from taking hold in this population; a population that is key to combating 
this deadly disease epidemic.  
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